<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Semin Immunol</journal-id>
      <journal-title-group>
        <journal-title>Seminars in Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1044-5323</issn>
      <issn pub-type="epub">1096-3618</issn>
      <publisher>
        <publisher-name>Academic Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3203219</article-id>
      <article-id pub-id-type="pmid">21616680</article-id>
      <article-id pub-id-type="publisher-id">YSMIM809</article-id>
      <article-id pub-id-type="doi">10.1016/j.smim.2011.04.002</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Costimulatory pathways in transplantation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pilat</surname>
            <given-names>Nina</given-names>
          </name>
          <xref rid="aff0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sayegh</surname>
            <given-names>Mohamed H.</given-names>
          </name>
          <xref rid="aff0010" ref-type="aff">b</xref>
          <xref rid="fn0005" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wekerle</surname>
            <given-names>Thomas</given-names>
          </name>
          <email>Thomas.Wekerle@meduniwien.ac.at</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
          <xref rid="fn0005" ref-type="fn">1</xref>
          <xref rid="cor0005" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff id="aff0005"><label>a</label>Division of Transplantation, Department of Surgery, Medical University of Vienna, Austria</aff>
      <aff id="aff0010"><label>b</label>Brigham and Women's Hospital &amp; Children's Hospital Boston, Harvard Medical School, Boston, USA</aff>
      <author-notes>
        <corresp id="cor0005"><label>⁎</label>Corresponding author at: Division of Transplantation, Department of Surgery, Vienna General Hospital, Waehringer Guertel 18, 1090 Vienna, Austria. Tel.: +43 1 40400 5621; fax: +43 1 40400 6872. <email>Thomas.Wekerle@meduniwien.ac.at</email></corresp>
        <fn id="fn0005">
          <label>1</label>
          <p>Co-senior authors of this manuscript.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <volume>23</volume>
      <issue>4</issue>
      <fpage>293</fpage>
      <lpage>303</lpage>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="graphical">
        <title>Highlights</title>
        <p>► Costimulatory pathways have a critical role in the regulation of alloreactivity. ► A complex network of positive and negative pathways regulates T cell responses. ► Blocking costimulation improves allograft survival in rodents and non-human primates. ► The costimulation blocker belatacept is being developed as immunosuppressive drug in renal transplantation.</p>
      </abstract>
      <abstract>
        <p>Secondary, so-called costimulatory, signals are critically required for the process of T cell activation. Since landmark studies defined that T cells receiving a T cell receptor signal without a costimulatory signal, are tolerized <italic>in vitro</italic>, the investigation of T cell costimulation has attracted intense interest. Early studies demonstrated that interrupting T cell costimulation allows attenuation of the alloresponse, which is particularly difficult to modulate due to the clone size of alloreactive T cells. The understanding of costimulation has since evolved substantially and now encompasses not only positive signals involved in T cell activation but also negative signals inhibiting T cell activation and promoting T cell tolerance. Costimulation blockade has been used effectively for the induction of tolerance in rodent models of transplantation, but turned out to be less potent in large animals and humans. In this overview we will discuss the evolution of the concept of T cell costimulation, the potential of ‘classical’ and newly identified costimulation pathways as therapeutic targets for organ transplantation as well as progress towards clinical application of the first costimulation blocking compound.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>T cell costimulation</kwd>
        <kwd>Costimulation blockade</kwd>
        <kwd>Transplantation</kwd>
        <kwd>Tolerance</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec0005">
      <label>1</label>
      <title>Introduction</title>
      <p>The development of new immunosuppressive drugs together with other innovations has lowered acute rejection rates and has improved short-term graft survival after organ transplantation, but long-term graft survival improved much less <xref rid="bib0005" ref-type="bibr">[1]</xref>. T cells play a central role in the immune response towards allografts <xref rid="bib0010" ref-type="bibr">[2]</xref>. Therefore, interfering with T cell activation offers the potential of prolonging graft survival through modulation of the alloresponse. The process of T cell activation is now recognized to involve multiple signals and distinctly regulated pathways. A 2-signal model was initially proposed by Lafferty and Cunningham in 1975 <xref rid="bib0015" ref-type="bibr">[3]</xref>. Signal 1 is delivered through the T-cell receptor (TCR) interacting with cognate antigen in the context of MHC and initiates the T cell activation process. Signal 1 alone is, however, insufficient for full T cell activation but rather leads to T cell anergy <xref rid="bib0020" ref-type="bibr">[4]</xref>. An additional signal 2 – the so-called costimulatory signal – provided by a number of specialised cell surface receptors is required for survival, clonal expansion and differentiation of activated T cells.</p>
      <p>The paradigm of T cell costimulation originally implicated that blocking costimulatory signals at the time of antigen encounter abrogates a T cell response and induces T cell anergy, an antigen-specific state of tolerance. Consequently great interest was triggered in exploiting the concept of T cell costimulation therapeutically with the goal of more selectively targeting the T cell allo-responses <xref rid="bib0025" ref-type="bibr">[5]</xref> and possibly even inducing immunologic tolerance <xref rid="bib0030" ref-type="bibr">[6]</xref>. Over the last two decades, noticable progress has indeed been made in the development of ‘costimulation blockers’ for the use in transplant recipients (which is discussed in more detail later) <xref rid="bib0030 bib0035" ref-type="bibr">[6,7]</xref>. In the meantime, our understanding of T cell costimulation at the molecular level has evolved considerably, too. It is now recognized that the spectrum of mechanisms triggered by costimulation blockade involves not only anergy, but also clonal deletion and regulation <xref rid="bib0040 bib0045" ref-type="bibr">[8,9]</xref>. Moreover, while costimulation blockade effectively induces allograft tolerance in selected rodent models <xref rid="bib0050 bib0055" ref-type="bibr">[10,11]</xref>, it has become evident that it is insufficient to do so in non-human primates (NHP) <xref rid="bib0060 bib0065 bib0070 bib0075" ref-type="bibr">[12–15]</xref>. Memory T cells – whose frequency is markedly higher in NHP than in laboratory rodents and which are less dependent on conventional costimulation signals – have been identified as a major factor in costimulation blockade-resistant rejection <xref rid="bib0080 bib0085" ref-type="bibr">[16,17]</xref>. Finally, with the identification of numerous additional costimulation pathways, including those that negatively regulate T cell activation, the concept of T cell costimulation is now much more complex and its therapeutic exploitation less straightforward than originally anticipated <xref rid="bib0090" ref-type="bibr">[18]</xref>.</p>
    </sec>
    <sec id="sec0010">
      <label>2</label>
      <title>Costimulatory pathways</title>
      <p>Costimulatory molecules can be categorized based either on their functional attributes or on their structure. The costimulatory molecules discussed in this review will be divided into (1) <italic>positive costimulatory pathways:</italic> promoting T cell activation, survival and/or differentiation; (2) <italic>negative costimulatory pathways:</italic> antagonizing TCR signalling and suppressing T cell activation; (3) as third group we will discuss the <italic>members of the TIM family</italic>, a rather “new” family of cell surface molecules involved in the regulation of T cell differentiation and Treg function. According to structure, costimulatory molecules can be broadly divided into 4 distinct groups: (i) the immunoglobulin (Ig) family (e.g. CD28, CTLA4, PD-1, ICOS), (ii) the TNF–TNFR family (e.g. CD40, CD137, OX40), (iii) the TIM family and (iv) cell adhesion molecules (e.g. CD2, LFA-1). In addition to discussing the “classical” targets of costimulation blockade (CD28, CD154), we will focus on selected other costimulation pathways with therapeutic potential in organ transplantation (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>).</p>
      <sec id="sec0015">
        <label>2.1</label>
        <title>Positive costimulatory pathways</title>
        <sec id="sec0020">
          <label>2.1.1</label>
          <title>Costimulatory molecules of the Ig family</title>
          <sec id="sec0025">
            <label>2.1.1.1</label>
            <title>CD28/B7 pathway</title>
            <p>The CD28 costimulation pathway is one of the best characterized and probably the most important one for naïve T cell activation in both mouse and humans. CD28 is a homodimeric transmembrane protein which is constitutively expressed on all T cell subsets in mice, and on 95% of CD4 and 50% of CD8 T cells in humans <xref rid="bib0095" ref-type="bibr">[19]</xref>. CD28 binds to B7.1 (CD80) which is inducibly expressed and B7.2 (CD86), which is constitutively expressed on the surface of APCs <xref rid="bib0100 bib0105" ref-type="bibr">[20,21]</xref>. B7.1 and B7.2 expression is also found on T cells <xref rid="bib0105" ref-type="bibr">[21]</xref>. Upon engagement with its ligands, CD28 provides a costimulatory signal triggering survival, proliferation and cytokine production of T cells. CD28/B7 ligation in the presence of TCR stimulation increases the expression of the IL2 receptor α-chain (CD25) and of CD40 ligand (CD40L and CD154), and induces cytokine production, including IL2 and interferon-γ (IFNγ). Furthermore, expression of anti-apoptotic molecules (e.g. Bcl-xL) is enhanced and IL2/CD25 binding activates the mammalian target of rapamycin (mTOR) pathway initiating T cell proliferation <xref rid="bib0110" ref-type="bibr">[22]</xref>. TCR stimulation in the absence of CD28 signalling induces classical T cell anergy <italic>in vitro</italic> <xref rid="bib0115" ref-type="bibr">[23]</xref>. Anergic T cells are functionally inactivated with reduced proliferation, differentiation and cytokine production <xref rid="bib0120" ref-type="bibr">[24]</xref>.</p>
            <p>Upon activation, T cells up-regulate the negative costimulatory molecule cytotoxic T-lymphocyte-associated-antigen 4 (CTLA4 and CD152), which shares ∼20% homology with CD28 and binds the same ligands as CD28, i.e. B7.1 and B7.2. Notably, CTLA4 binds B7 molecules with higher avidity and affinity, thereby outcompeting CD28 and preventing its ligation. Moreover, the intracellular CTLA4 signal directly antagonizes CD28 signalling by inhibiting AKT <xref rid="bib0095" ref-type="bibr">[19]</xref>. Thus, CTLA4 provides a negative feedback loop that down-regulates T cell responses <xref rid="bib0125 bib0130" ref-type="bibr">[25,26]</xref>. Besides, CTLA4 is constitutively expressed on FoxP3<sup>+</sup> Tregs and is critical for their suppressor function <xref rid="bib0135 bib0140" ref-type="bibr">[27,28]</xref>. CTLA4-dependent ligation of B7 also transmits outside-in signals to the APC, down-modulating expression of B7 molecules <xref rid="bib0145" ref-type="bibr">[29]</xref> and up-regulating the tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO) <xref rid="bib0150" ref-type="bibr">[30]</xref>.</p>
            <p>As direct blockade of CD28 with anti-CD28 mAbs turned out to be difficult due to unwanted agonistic ‘side effects’, alternative strategies were sought and resulted in the development of the fusion protein CTLA4Ig <xref rid="bib0155" ref-type="bibr">[31]</xref>. This fusion protein consists of the extracellular CTLA4 domain and the Fc portion of IgG1. Due to its higher affinity CTLA4Ig prevents CD28 signals by outcompeting CD28 for binding to its only ligands CD80/86 <xref rid="bib0160" ref-type="bibr">[32]</xref>. At the time when CTLA4Ig was designed, the higher binding affinity but not the physiologic function of CTLA4 as negative regulator had been revealed <xref rid="bib0165" ref-type="bibr">[33]</xref>. Only later it was recognized that blocking CD80/86 also prevents ligation of CTLA4 and thus prevents a negative costimulatory signal to the T cell. CTLA4Ig (abatacept) has since been approved for the treatment of rheumatoid arthritis <xref rid="bib0170" ref-type="bibr">[34]</xref> and a second generation CTLA4Ig, belatacept <xref rid="bib0175" ref-type="bibr">[35]</xref>, is close to clinical approval for renal transplantation (see below) <xref rid="bib0180 bib0185" ref-type="bibr">[36,37]</xref>. Another approach to target CD28 was the development of anti-CD80/86 monoclonal antibodies (mAb). Anti-CD80/86 prolonged renal allograft survival in non-human primates (NHP) <xref rid="bib0190 bib0195" ref-type="bibr">[38,39]</xref> and were tested in a phase I clinical trial <xref rid="bib0200" ref-type="bibr">[40]</xref>. Further development seems uncertain <xref rid="bib0140" ref-type="bibr">[28]</xref> in particular in view of CTLA4's role in the induction of peripheral tolerance <xref rid="bib0205" ref-type="bibr">[41]</xref>.</p>
            <p><italic>In vivo</italic> blockade of CD28 with CTLA4Ig potently prolongs allograft survival in numerous rodent models <xref rid="bib0210 bib0215 bib0220" ref-type="bibr">[42–44]</xref>. CTLA4Ig induces long-term survival of heart <xref rid="bib0220 bib0225" ref-type="bibr">[44,45]</xref>, islet <xref rid="bib0230" ref-type="bibr">[46]</xref> and renal grafts <xref rid="bib0235 bib0240" ref-type="bibr">[47,48]</xref>, although donor splenocyte transfusion (DST) – promoting the generation of Tregs <xref rid="bib0245" ref-type="bibr">[49]</xref> – was required for the induction of robust tolerance in most models <xref rid="bib0215" ref-type="bibr">[43]</xref>. CTLA4Ig synergizes with other costimulation blockers, most notably with anti-CD154 <xref rid="bib0050" ref-type="bibr">[10]</xref>. The timing of CTLA4Ig administration influences its effects with delayed administration leading to superior results <xref rid="bib0215" ref-type="bibr">[43]</xref>, probably by allowing up-regulation and engagement of CTLA4 <xref rid="bib0045 bib0250" ref-type="bibr">[9,50]</xref>. Although CTLA4Ig is highly effective in rodent models, it does not lead to skin graft tolerance across MHC barriers <xref rid="bib0050 bib0210" ref-type="bibr">[10,42]</xref>. Translation of CTLA4Ig therapy into NHP was disappointing at first, with only modest prolongation of allograft survival <xref rid="bib0060 bib0255" ref-type="bibr">[12,51]</xref>, which prompted the development of belatacept, a 2nd generation CTLA4Ig with increased binding affinity <xref rid="bib0175" ref-type="bibr">[35]</xref>. Recently, alefacept, a dimeric fusion protein consisting of the CD2-binding portion of the human lymphocyte function-associated antigen-3 (LFA-3) linked to the Fc portion of human IgG1, was found to act synergistically with CTLA4Ig in NHP renal transplantation <xref rid="bib0260" ref-type="bibr">[52]</xref>. Alloreactive CD8 T cells progressively lose CD28 expression upon activation, becoming increasingly insensitive to CD28 blockade by CTLA4Ig/belatacept. However, since they upregulate CD2 in this process, alefacept effectively targets those effector/memory CD8 cells that are not controlled by CTLA4Ig/belatacept <xref rid="bib0265" ref-type="bibr">[53]</xref>. As alefacept is clinically approved for the treatment of psoriasis, this combination of treatments offers immediate potential for clinical translation.</p>
            <p>Recently, interest in CD28-specific mAbs was rekindled. Two types of <italic>agonistic</italic> anti-CD28 mAbs can be distinguished <xref rid="bib0270" ref-type="bibr">[54]</xref>: superagonistic anti-CD28 mAbs induce full T cell activation even in the absence of TCR stimulation, whereas conventional (agonistic) anti-CD28 mAbs provide a costimulatory signal only in combination with TCR stimulation. Superagonistic anti-CD28 mAb leads to the preferential activation and expansion of Tregs <italic>in vitro</italic> and <italic>in vivo</italic> <xref rid="bib0275 bib0280" ref-type="bibr">[55,56]</xref>. Agonistic anti-CD28 mAbs prevent autoimmune diseases <xref rid="bib0285" ref-type="bibr">[57]</xref>, GVHD <xref rid="bib0290" ref-type="bibr">[58]</xref> and prolong allograft survival <xref rid="bib0295 bib0300" ref-type="bibr">[59,60]</xref> in rodent models. Clinical development of superagonistic anti-CD28 had to be stopped, however, after catastrophic results from a phase I trial. Six healthy volunteers experienced a massive cytokine storm upon administration of a superagonistic anti-CD28 mAb <xref rid="bib0305" ref-type="bibr">[61]</xref>. In rodents, in sharp contrast, superagonistic anti-CD28 therapy had not been associated with massive release of pro-inflammatory cytokines <xref rid="bib0285" ref-type="bibr">[57]</xref>, presumably because activation and expansion of Tregs effectively suppressed the inflammatory response <xref rid="bib0310" ref-type="bibr">[62]</xref>. Recently, progress was reported in the development of mAbs <italic>blocking</italic> CD28 without agonistic activity. A monovalent single chain antibody (sc28AT) prevented T cell proliferation and cytokine production <italic>in vitro</italic> and synergized with CNIs to prevent acute and chronic allograft rejection in NHP models <xref rid="bib0315" ref-type="bibr">[63]</xref>. By selectively blocking CD28, CTLA4 (and presumably PDL-1) signals remain intact and contribute to the immunomodulatory effects.</p>
          </sec>
          <sec id="sec0030">
            <label>2.1.1.2</label>
            <title>ICOS/B7h pathway</title>
            <p>The CD28 homolog inducible costimulatory molecule (ICOS) is expressed upon activation in CD4<sup>+</sup> and CD8<sup>+</sup> T cells and persists in effector and memory T cells <xref rid="bib0320 bib0325" ref-type="bibr">[64,65]</xref>. ICOS binds to its ligand B7h (B7 homolog; B7-H2, ICOSL) which is structurally related to B7-1/2 but does not bind to CD28 or CTLA4 <xref rid="bib0330" ref-type="bibr">[66]</xref>. Signalling through ICOS enhances T cell proliferation, survival and cytokine production and is important for T–B cell interactions, providing help to B cells <xref rid="bib0335" ref-type="bibr">[67]</xref>. ICOS expression on B cells is involved in the immunoglobulin class switch <xref rid="bib0320" ref-type="bibr">[64]</xref>, germinal center formation and memory B cell generation <xref rid="bib0105" ref-type="bibr">[21]</xref>. Furthermore ICOS is upregulated on NK cells, promoting NK cell function <xref rid="bib0340" ref-type="bibr">[68]</xref>.</p>
            <p>ICOS is expressed on both Th1 and Th2 cells, however expression is higher on Th2 cells. In non-transplant settings, ICOS blockade effectively inhibits Th2 responses through mechanisms requiring intact CTLA4 and STAT6 signalling pathways <xref rid="bib0345" ref-type="bibr">[69]</xref>. A critical role for ICOS in Th1 responses was not observed in models examining primary and recall responses <xref rid="bib0350" ref-type="bibr">[70]</xref> but it seems to regulate CD28-independent anti-viral Th1 and Th2 responses and cytokine proliferation <xref rid="bib0355" ref-type="bibr">[71]</xref>. Anti-ICOS mAbs prolong cardiac allograft survival <xref rid="bib0360" ref-type="bibr">[72]</xref>, with timing of ICOS blockade being a critical factor as only delayed blockade suppresses effector CD8<sup>+</sup> T cell generation and significantly extends allograft survival <xref rid="bib0345" ref-type="bibr">[69]</xref>. ICOS blockade prolongs allograft survival to a lesser degree than anti-CD40L mAbs or CTLA4Ig <xref rid="bib0360" ref-type="bibr">[72]</xref>, but combined treatment with either of these results in long-term cardiac allograft survival and prevents chronic rejection <xref rid="bib0365" ref-type="bibr">[73]</xref>. Thus co-blockade of ICOS/B7h and CD28/B7 or CD40/CD40L has synergistic effects on the prevention of allograft rejection.</p>
          </sec>
        </sec>
        <sec id="sec0035">
          <label>2.1.2</label>
          <title>Costimulatory molecules of the TNF/TNFR family</title>
          <sec id="sec0040">
            <label>2.1.2.1</label>
            <title>CD40/CD154 pathway</title>
            <p>In addition to CD28/B7, the CD40/CD154 (CD40L) pathway is the second major pathway on which interest focuses in transplantation medicine. CD40 is a member of the TNFR superfamily and is constitutively expressed – at low levels – on the surface of APCs, including B cells, endothelial cells and fibroblasts <xref rid="bib0370" ref-type="bibr">[74]</xref> and is significantly upregulated upon activation <xref rid="bib0375" ref-type="bibr">[75]</xref>. Ligation of CD40 is critical for DC activation and maturation as well as for B cell activation and the immunoglobulin class switch. Downstream signalling of CD40 leads to up-regulation of MHC molecules and costimulatory molecules of the B7 family as well as increased inflammatory cytokine production <xref rid="bib0090" ref-type="bibr">[18]</xref>. CD154 (CD40L) – the only known ligand of CD40 – belongs to the TNF superfamily, is expressed on activated T cells (including iNKT cells) and subsets of NK cells, eosinophils and platelets <xref rid="bib0370" ref-type="bibr">[74]</xref>. To date, it has still not been fully resolved whether CD40L transmits a signal to T cells, which is of particular interest with regard to the development of antibodies to CD40L/CD40 <xref rid="bib0380 bib0385 bib0390 bib0395 bib0400" ref-type="bibr">[76–80]</xref>. Mutations in the CD40 or the CD40L gene cause the hyper IgM syndrome, an immunodeficiency disorder characterized by defects of immunoglobulin class switch recombination, with or without defects of somatic hypermutation leading to humoral immunodeficiency and a susceptibility to opportunistic infections <xref rid="bib0405" ref-type="bibr">[81]</xref>.</p>
            <p>Increased levels of CD40 (upon activation) result in increased CD40/CD154 interactions and an increased strength of antigen specific signals, making interruption of this pathway an attractive therapeutic target in autoimmune diseases <xref rid="bib0410" ref-type="bibr">[82]</xref> and allograft rejection <xref rid="bib0025 bib0090" ref-type="bibr">[5,18]</xref>. Blockade of CD40/CD154 costimulation (by either anti-CD154 mAb or genetic knockout) is exceptionally effective in experimental transplantation models <xref rid="bib0045" ref-type="bibr">[9]</xref>, preventing acute rejection and prolonging allograft survival <xref rid="bib0415" ref-type="bibr">[83]</xref>. However, CD40/CD154 blockade on its own does not prevent chronic rejection <xref rid="bib0420 bib0425" ref-type="bibr">[84,85]</xref>. The therapeutic efficacy of CD40/CD154 blockade is increased through combination with a number of other therapies, in particular DST, CTLA4Ig and rapamycin <xref rid="bib0430" ref-type="bibr">[86]</xref>. Combining anti-CD154 mAbs with DST leads to donor-specific tolerance without signs of chronic rejection in murine models of islet and cardiac allograft transplantation <xref rid="bib0050" ref-type="bibr">[10]</xref>. Although CTLA4Ig was shown to synergize with anti-CD154 mAb <xref rid="bib0050" ref-type="bibr">[10]</xref>, long-term skin graft survival was not achieved when stringent strain combinations were used <xref rid="bib0435 bib0440" ref-type="bibr">[87,88]</xref>.</p>
            <p>Monoclonal antibodies specific for CD154 have shown great promise in both rodent and early NHP models <xref rid="bib0050 bib0060 bib0065 bib0445" ref-type="bibr">[10,12,13,89]</xref>. Unexpectedly, however, anti-humanCD154 antibodies were associated with severe thromboembolic complications in a phase I trial <xref rid="bib0450" ref-type="bibr">[90]</xref> (and subsequent NHP studies <xref rid="bib0455" ref-type="bibr">[91]</xref>). Clinical development of anti-CD154 mAbs was suspended indefinitely. The pro-thrombotic effects of anti-CD154 mAbs were identified to involve the expression of CD154 on platelets where it participates in the stabilization of thrombi <xref rid="bib0460" ref-type="bibr">[92]</xref>. Anti-CD40 mAbs are an alternative approach for blocking CD40/CD154 costimulatory signals without interfering with the aggregation of platelets. Results obtained with newly designed anti-CD40 mAbs are encouraging <xref rid="bib0465 bib0470" ref-type="bibr">[93,94]</xref>. A chimeric anti-CD40 mAb (Chi220) substantially prolongs islet allograft survival in rhesus macaques, acting synergistically with belatacept <xref rid="bib0465" ref-type="bibr">[93]</xref>. Several anti-CD40 mAbs are currently under investigation, with at least one of them having recently entered clinical development (ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="ctgov:NCT01279538">NCT01279538</ext-link>).</p>
          </sec>
          <sec id="sec0045">
            <label>2.1.2.2</label>
            <title>OX40/OX40L</title>
            <p>The costimulatory molecule OX40 (CD134) belongs to the TNFR family, is expressed on activated T cells <xref rid="bib0475" ref-type="bibr">[95]</xref> (preferentially on CD4<sup>+</sup> T cells including activated Tregs) and mediates T cell differentiation, proliferation and survival <xref rid="bib0480" ref-type="bibr">[96]</xref>. OX40 ligand (OX40L) is expressed on activated dendritic cells, B cells and vascular epithelial cells <xref rid="bib0485" ref-type="bibr">[97]</xref>. Signalling through the OX40/OX40L pathway is critical for humoral immune responses and enhances B cell proliferation and differentiation <xref rid="bib0485" ref-type="bibr">[97]</xref>. OX40 costimulation is not dependent on intact CD28 signalling although CD28 signal up-regulates OX40 expression on T cells <xref rid="bib0490" ref-type="bibr">[98]</xref>. OX40 has a critical role in regulating differentiation programs for Th1/Th2 as well as memory T cell generation <xref rid="bib0480 bib0495 bib0500" ref-type="bibr">[96,99,100]</xref>.</p>
            <p>Blockade of the OX40/OX40L pathway (using anti-OX40L mAbs) has little effect on the survival of allografts. However, OX40 plays a critical role in CD28- and CD40-independent rejection as anti-OX40L prolongs allograft survival in CD28/CD40L double deficient mice <xref rid="bib0505" ref-type="bibr">[101]</xref> and synergizes with CD154- and/or CD28-blockade to prevent allograft rejection <xref rid="bib0505 bib0510" ref-type="bibr">[101,102]</xref>. Although OX40 signalling seems to have little impact on primary T cell responses <xref rid="bib0505" ref-type="bibr">[101]</xref>, it is important for the survival of activated T cells and memory T cell generation <xref rid="bib0515" ref-type="bibr">[103]</xref>. Thus, OX40 blockade is a potent candidate for targeting CD154/CD28 costimulation blockade-resistant memory cells <xref rid="bib0520 bib0525" ref-type="bibr">[104,105]</xref>, which are a major concern in clinical transplantation <xref rid="bib0530" ref-type="bibr">[106]</xref>.</p>
            <p>Of note, OX40 is constitutively expressed on both natural and induced Tregs and plays a pivotal role in Treg generation and suppressor function <xref rid="bib0535 bib0540 bib0545" ref-type="bibr">[107–109]</xref>. In contrast to its positive costimulatory role in effector T cells, signalling through the OX40/OX40L pathway leads to negative costimulation in Tregs. OX40 ligation leads to decreased FoxP3 expression and loss of suppressor function <italic>in vitro</italic> and <italic>in vivo</italic> <xref rid="bib0550" ref-type="bibr">[110]</xref>. Moreover, OX40 costimulation prevents the <italic>de novo</italic> induction of iTregs by TGFβ <xref rid="bib0550" ref-type="bibr">[110]</xref> and the generation of Tr1 regulatory cells <xref rid="bib0555" ref-type="bibr">[111]</xref>. Thus, OX40 signals promote effector cells and shut down regulatory T cells.</p>
          </sec>
          <sec id="sec0050">
            <label>2.1.2.3</label>
            <title>4-1BB/4-1BBL pathway</title>
            <p>4-1BB (CD137) is also a member of the TNFR family, primarily expressed on activated T cells <xref rid="bib0560" ref-type="bibr">[112]</xref>, mediating T cell activation, differentiation and survival upon engagement <xref rid="bib0565 bib0570" ref-type="bibr">[113,114]</xref>. Its ligand 4-1BBL is expressed on mature DC, activated B cells and macrophages. The 4-1BB/4-1BBL pathway is suggested to contribute to skin allograft rejection in the absence of CD28 signalling, and is critical for cytotoxic T lymphocyte (CTL) responses <xref rid="bib0575 bib0580" ref-type="bibr">[115,116]</xref>.</p>
            <p>The role of the 4-1BB costimulatory pathway with regard to transplantation varies between models. Blocking the 4-1BB signal with 4-1BB-Ig, anti-4-1BBL mAbs or genetic knockdown leads to prolongation of cardiac and intestinal allograft survival, whereas skin grafts are still promptly rejected <xref rid="bib0585 bib0590" ref-type="bibr">[117,118]</xref>. The bulk of data suggests that 4-1BB costimulatory signals play an eminent role in CD8<sup>+</sup> T cell mediated allograft rejection <xref rid="bib0025" ref-type="bibr">[5]</xref>.</p>
          </sec>
          <sec id="sec0055">
            <label>2.1.2.4</label>
            <title>GITR/GITRL pathway</title>
            <p>The glucocorticoid-induced TNF-R family related gene (GITR) is expressed at high levels on CD4<sup>+</sup> and CD8<sup>+</sup> T cells upon activation, whereas Tregs constitutively express GITR <xref rid="bib0595" ref-type="bibr">[119]</xref>. GITR is suggested to be involved in Treg survival and function as anti-GITR leads to loss of suppressive function <italic>in vitro</italic> <xref rid="bib0600 bib0605" ref-type="bibr">[120,121]</xref>. In conventional T cells GITR/GITRL costimulatory signals promote T cell proliferation and cytokine production. However, its role in transplantation still needs to be clarified <xref rid="bib0610 bib0615" ref-type="bibr">[122,123]</xref>.</p>
          </sec>
        </sec>
        <sec id="sec0060">
          <label>2.1.3</label>
          <title>Cell adhesion molecules</title>
          <sec id="sec0065">
            <label>2.1.3.1</label>
            <title>LFA-1/ICAM pathway</title>
            <p>Leukocyte function-associated antigen-1 (LFA-1) is a β2 integrin heterodimer consisting of the unique α chain CD11a and the common β chain CD18. LFA-1 binds to intracellular adhesion molecules, primarily ICAM-1. LFA-1 is involved in T cell trafficking, immunological synapse formation and costimulation <xref rid="bib0620" ref-type="bibr">[124]</xref>. In addition to promoting optimal T cell activation through stabilization of the T/APC contact during TCR engagement, LFA-1 appears to deliver direct costimulatory signals <xref rid="bib0625" ref-type="bibr">[125]</xref> involved in T cell activation and CTL function <xref rid="bib0630 bib0635" ref-type="bibr">[126,127]</xref>. LFA-1 is also expressed on B cells <xref rid="bib0640" ref-type="bibr">[128]</xref> and upregulated on memory T cells <xref rid="bib0645" ref-type="bibr">[129]</xref>, suggesting therapeutic potency in targeting CD154/CD28 costimulation blockade-resistant memory cells.</p>
            <p>Blockade of LFA-1 (by anti-LFA-1 mAbs) synergizes with other costimulation blockers and immunosuppressive drugs in prolonging survival of islet, cardiac and skin allografts and in preventing GVHD <xref rid="bib0650 bib0655 bib0660 bib0665 bib0670 bib0675" ref-type="bibr">[130–135]</xref>. An anti-LFA-1 mAb disappointed in early clinical pilot trials of adult BMT <xref rid="bib0680" ref-type="bibr">[136]</xref> and data on the efficacy in solid organ transplantation remain controversial <xref rid="bib0685 bib0690" ref-type="bibr">[137,138]</xref>. A humanized anti-LFA-1 (i.e. anti-CD11a, efalizumab) mAb was effective in the treatment of psoriasis and was approved by the FDA for this indication <xref rid="bib0695 bib0700" ref-type="bibr">[139,140]</xref>. Efalizumab reversibly blocks LFA-1/ICAM-1, resulting in reduced T cell activation and impaired T cell trafficking <xref rid="bib0705" ref-type="bibr">[141]</xref>. However, efalizumab was withdrawn from the market due to safety concerns <xref rid="bib0090" ref-type="bibr">[18]</xref>. Given the encouraging efficacy results of efalizumab in autoimmune disease, LFA-1 was reconsidered as therapeutic target in transplantation and LFA-1 blockade has recently been reported to prolong cardiac and islet allograft survival in NHP <xref rid="bib0710 bib0715" ref-type="bibr">[142,143]</xref>.</p>
          </sec>
        </sec>
      </sec>
      <sec id="sec0070">
        <label>2.2</label>
        <title>Negative costimulatory pathways</title>
        <sec id="sec0075">
          <label>2.2.1</label>
          <title>CTLA4/B7</title>
          <p>CTLA4 (CD152) is a member of the Ig superfamily and shares ligands B7.1 and B7.2 (with a preference for B7.1 <xref rid="bib0720" ref-type="bibr">[144]</xref>) with the structurally related CD28, but has a 10–20-fold higher binding affinity <xref rid="bib0720" ref-type="bibr">[144]</xref>. In contrast to CD28, CTLA4 is expressed only by activated T cells, but not by naive, resting T cells <xref rid="bib0100" ref-type="bibr">[20]</xref>. However, CTLA4 is constitutively expressed at high levels by Tregs, where it is critical for their suppressive function <xref rid="bib0140 bib0725" ref-type="bibr">[28,145]</xref>. Both naive CD4<sup>+</sup>CD25<sup>−</sup> T cells and memory T cells up-regulate CTLA4 upon stimulation, however expression declines rapidly in CD4<sup>+</sup>CD25<sup>−</sup> T cells <xref rid="bib0730" ref-type="bibr">[146]</xref>. Engagement of CTLA4 delivers a negative costimulatory signal (co-inhibitory signal), inhibiting TCR- and CD28-mediated signal transduction, leading to suppression of T cell activation and the induction of T cell anergy <xref rid="bib0105 bib0125 bib0735" ref-type="bibr">[21,25,147]</xref>. The importance of CTLA4 as central negative regulator of T cell responses is underlined by the fact that CTLA4 knockout mice rapidly die from lymphoproliferative disease due to uncontrolled B7 costimulation <xref rid="bib0740 bib0745 bib0750" ref-type="bibr">[148–150]</xref>. The details coordinating the balance between costimulatory signals through CD28 and CTLA4 during an immune response still need to be clarified. CTLA4 plays an important role in attenuating alloresponses and promoting tolerance induction. Importantly, an intact CTLA4 pathway is critical for tolerance induction even in the absence of a CD28/B7 costimulatory signal <xref rid="bib0025 bib0755" ref-type="bibr">[5,151]</xref>. In light of this pro-tolerogenic function of CTLA4, the therapeutic use of CTLA4Ig raises concerns as it blocks a potentially beneficial CTLA4 signal through saturating B7 <xref rid="bib0100" ref-type="bibr">[20]</xref>. Indeed, blocking CTLA4 experimentally results in abrogation of tolerance, highlighting its importance for tolerance induction/maintenance <xref rid="bib0205 bib0760" ref-type="bibr">[41,152]</xref>. Deliberate ligation of CTLA4 could suppress allogeneic T cell responses. However, most soluble anti-CTLA4 mAbs lack agonistic properties and rather block CTLA4 signals when used <italic>in vivo</italic>. Membrane-bound anti-CTLA4 mAbs with ligating properties resembling natural B7-1, in contrast, were effective in down-modulating allogeneic T cell responses <italic>in vivo</italic> <xref rid="bib0755" ref-type="bibr">[151]</xref>.</p>
          <sec id="sec0080">
            <label>2.2.1.1</label>
            <title>PD-1/PD-L1/2</title>
            <p>Programmed death-1 (PD-1) belongs to the Ig superfamily and shares homology with CTLA4 and CD28. It is inducibly expressed as monomer on activated T cells, activated B cells, NK cells and macrophages <xref rid="bib0105" ref-type="bibr">[21]</xref> and binds to PD-L1 (B7-H1) and PD-L2 (B7-DC). PD-L1 is constitutively expressed on T cells (including Tregs), B cells, myeloid cells (including mast cells) and dendritic cells and can be upregulated upon activation <xref rid="bib0765" ref-type="bibr">[153]</xref>. In contrast to B7-1/2, PD-L1 is also expressed on non-hematopoietic cells and non-lymphoid organs (heart, lung, and muscle) where it is suggested to regulate peripheral tolerance <xref rid="bib0770" ref-type="bibr">[154]</xref>. Notably, PD-L1 has recently been identified as additional ligand for B7.1 <xref rid="bib0775" ref-type="bibr">[155]</xref>. Functional studies suggested that the B7-1:PD-L1 interaction inhibits T cell proliferation and cytokine production <xref rid="bib0775" ref-type="bibr">[155]</xref>. Expression of PD-L2 is inducible by cytokines and restricted to macrophages, mast cells and dendritic cells <xref rid="bib0105" ref-type="bibr">[21]</xref>. The fact that PD-L1/2 is expressed on mast cells suggests a role for the PD-1/PD-L1/2 pathway in Treg/mast cell interactions in peripheral tolerance <xref rid="bib0780 bib0785" ref-type="bibr">[156,157]</xref>. Moreover, PD-L1 promotes Treg development and function <xref rid="bib0790" ref-type="bibr">[158]</xref>, implicating PD-1 as attractive therapeutic target in autoimmune diseases and tolerance induction <xref rid="bib0795" ref-type="bibr">[159]</xref>. PD-1 signals inhibit T cell activation, proliferation and cytokine production by mechanisms distinct from CTLA4 <xref rid="bib0800" ref-type="bibr">[160]</xref>. Co-localization of PD-1 and TCR/CD28 is required for PD-1 mediated inhibition and can be overcome by exogenous IL2 <xref rid="bib0805" ref-type="bibr">[161]</xref>. The importance of PD-1 as potent regulator of T and B cell responses is demonstrated by PD-1 knockout mice that develop lymphoproliferative/autoimmune disease <xref rid="bib0810 bib0815" ref-type="bibr">[162,163]</xref>.</p>
            <p>The role of the PD-1/PD-L1/2 pathway in transplantation is rather complex and incompletely understood <xref rid="bib0025" ref-type="bibr">[5]</xref>. Expression of PD-1 and its ligands is upregulated in cardiac allografts during acute rejection <xref rid="bib0820" ref-type="bibr">[164]</xref>. PD-L1Ig (but not PD-L2Ig) was shown to synergize with anti-CD154 or rapamycin in preventing rejection of cardiac and islet allografts <xref rid="bib0820 bib0825" ref-type="bibr">[164,165]</xref>. However, other studies have shown that PD-L1/2 can trigger stimulatory signals, which may be related to the widespread tissue expression of PD-1 ligands <xref rid="bib0025 bib0105" ref-type="bibr">[5,21]</xref>. Thus, although PD-1 is a promising therapeutic target, the exact roles of PD-1 and its ligands in allograft rejection still need to be determined before its potential can be realized.</p>
          </sec>
          <sec id="sec0085">
            <label>2.2.1.2</label>
            <title>BTLA/CD160/HVEM</title>
            <p>B and T lymphocyte attenuator (BTLA; CD272) is a member of the Ig superfamily and is expressed in the thymus and in the bone marrow during T cell and B cell development, respectively. BTLA is constitutively expressed at low levels on naïve T and B cells, NK cells, macrophages and dendritic cells and is up-regulated on activated T cells. Unlike CTLA4 and PD-L1, BTLA is not expressed on Tregs <xref rid="bib0830" ref-type="bibr">[166]</xref>. Interestingly, BTLA binds to herpes virus-entry mediator (HVEM), a member of the TNFR family expressed on activated T cells, B cells and NK cells <xref rid="bib0835 bib0840" ref-type="bibr">[167,168]</xref>. The co-inhibitory signal through BTLA/HVEM suppresses T cell activation and differentiation <italic>in vitro</italic> <xref rid="bib0845" ref-type="bibr">[169]</xref>, but little is currently known about its role regarding B cells and NK cells regulation.</p>
            <p>CD160, also a new member of the Ig superfamily, is the second co-inhibitory ligand of HVEM. It is constitutively expressed in subsets of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells and NKT cells and is upregulated upon activation <xref rid="bib0830 bib0850" ref-type="bibr">[166,170]</xref>. Engagement of CD160 and HVEM suppresses T cell activation and proliferation upon CD3/CD28 stimulation <italic>in vitro</italic> <xref rid="bib0855" ref-type="bibr">[171]</xref>. The balance between negative costimulatory signals through BTLA/HVEM and CD160/HVEM engagement and positive costimulatory signals through LIGHT/HVEM or LTβR/HVEM contributes to allogeneic T cell regulation, however the exact mechanisms still have to be determined. Although binding affinity of HVEM is higher for LIGHT than for BTLA and CD160, co-inhibitory functions are dominant over costimulatory functions. This complex pathway highlights the importance of differences in ligand/receptor binding affinity and distinct expression patterns of these molecules in immune response regulation <xref rid="bib0850" ref-type="bibr">[170]</xref>.</p>
            <p>Targeting the BTLA/HVEM/CD80 pathway in transplantation models prolongs survival of heart <xref rid="bib0860" ref-type="bibr">[172]</xref> and islet allografts <xref rid="bib0865 bib0870" ref-type="bibr">[173,174]</xref>, with the outcome depending on the degree of MHC mismatch <xref rid="bib0875" ref-type="bibr">[175]</xref>. Blockade of BTLA at the time of hematopoietic stem cell transplantation prevents GVHD, but is not sufficient to reverse ongoing disease <xref rid="bib0880" ref-type="bibr">[176]</xref>. Different approaches have been employed for targeting the BTLA/HVEM/CD160 pathway including non-depleting antagonistic mAb blocking HVEM (anti-HVEM mAb, anti-LIGHT mAb, anti-LTβR), non-depleting agonistic mAbs signalling through co-inhibitory receptors (anti-BTLA mAb, anti-CD160 mAb) and depleting mAbs against CD160 and LIGHT in combination with therapies that inhibit CD4<sup>+</sup> T cell-mediated alloresponses <xref rid="bib0830" ref-type="bibr">[166]</xref>. The therapeutic efficiency and possible interactions with other costimulatory pathways still need to be determined.</p>
          </sec>
        </sec>
      </sec>
      <sec id="sec0090">
        <label>2.3</label>
        <title>TIM family molecules</title>
        <p>T cell immunoglobulin (Ig) and mucin domain (TIM) molecules are members of the type I transmembrane glycoprotein family. Initially, TIM molecules were identified as cell-surface proteins for differentiation between Th1 and Th2 cells, but soon they gained a lot of attention as putative therapeutic targets for immune regulation in autoimmune and allergic diseases <xref rid="bib0885 bib0890" ref-type="bibr">[177,178]</xref>. The TIM family has 8 known members in mice (TIM 1–4 and putative TIM 5–8) and 3 members in humans (TIM 1, 3 and 4), all of them encoding transmembrane proteins that have an IgV domain, a mucin-like domain and a cytoplasmic tail. The TIM molecules have broad immunological functions, including T cell activation, induction of T cell apoptosis and T cell tolerance, and the capacity of APCs to clear apoptotic cells <xref rid="bib0895" ref-type="bibr">[179]</xref>.</p>
        <sec id="sec0095">
          <label>2.3.1</label>
          <title>TIM 1/TIM 4</title>
          <p>In mice, TIM 1 is inducibly expressed on activated CD4<sup>+</sup> T cells. Upon differentiation only Th2 cells constitutively express TIM 1 whereas Th1 and Th17 cells lose TIM 1 expression <xref rid="bib0895 bib0900" ref-type="bibr">[179,180]</xref>. TIM 1 is also expressed on mast cells <xref rid="bib0905" ref-type="bibr">[181]</xref> and some B cells <xref rid="bib0910" ref-type="bibr">[182]</xref>. Human TIM 1 was originally described as cellular receptor for hepatitis A virus (HAVCR) <xref rid="bib0915" ref-type="bibr">[183]</xref> and is also known as kidney injury molecule 1 (KIM1), which is highly upregulated after ischemia/reperfusion injury <xref rid="bib0920" ref-type="bibr">[184]</xref>. Several ligands have been identified, among them TIM 1 itself <xref rid="bib0925" ref-type="bibr">[185]</xref>, TIM 4 <xref rid="bib0930" ref-type="bibr">[186]</xref>, IgAλ <xref rid="bib0935" ref-type="bibr">[187]</xref> and phosphatidylserine <xref rid="bib0940" ref-type="bibr">[188]</xref>. Unlike other TIM family members, TIM 4 is constitutively expressed on APCs but not on T cells and lacks a cytoplasmic signalling motif <xref rid="bib0930" ref-type="bibr">[186]</xref>. Engagement of TIM 1 delivers costimulatory signals involved in T cell proliferation, survival and cytokine production <xref rid="bib0900" ref-type="bibr">[180]</xref>. Different TIM 1 mAbs recognizing distinct epitopes of TIM 1 as well as different binding affinities have profoundly different effects on the type of response that is induced <xref rid="bib0895" ref-type="bibr">[179]</xref>. Additionally, TIM 1 costimulation abrogates suppressor function in Tregs and reduces FoxP3 expression, thereby preventing Treg generation. As agonist anti-TIM 1 mAb enhances Th17 differentiation, TIM 1 is suggested to play a major role in regulating the balance between Tregs and Th17 cell conversion <xref rid="bib0945" ref-type="bibr">[189]</xref>.</p>
          <p>While agonist anti-TIM 1 mAbs prevent tolerance induction in an islet allograft model <xref rid="bib0945" ref-type="bibr">[189]</xref>, low affinity anti-TIM mAb synergizes with rapamycin to prolong cardiac allograft survival by inhibition of the alloreactive Th1 responses <xref rid="bib0950" ref-type="bibr">[190]</xref>. TIM 1 costimulation modulates the T cell response by inducing a Th1- to Th2-type cytokine switch, and by regulating the Treg/Th17 balance, however the exact mechanisms have yet to be defined.</p>
        </sec>
        <sec id="sec0100">
          <label>2.3.2</label>
          <title>TIM 3</title>
          <p>TIM 3 is expressed on Th1 and Th17 cells but not on resting T cells or Th2 cells <xref rid="bib0955 bib0960" ref-type="bibr">[191,192]</xref>. Moreover, TIM 3 is constitutively expressed by cells of the innate immune system mast cells, macrophages and dendritic cells <xref rid="bib0965 bib0970" ref-type="bibr">[193,194]</xref>. TIM 3 binds to galectin 9, which is predominantly expressed on Tregs and on naive CD4<sup>+</sup> T cells—where it is down-regulated upon activation. Engagement of TIM 3/galectin 9 inhibits Th1 responses by induction of cell death <xref rid="bib0975" ref-type="bibr">[195]</xref> and also inhibits Th17 differentiation <italic>in vitro</italic> <xref rid="bib0980" ref-type="bibr">[196]</xref>.</p>
          <p>Blocking TIM 3 costimulation by anti-TIM 3 mAbs or TIM 3Ig accelerates the development of autoimmune disease and abrogates tolerance in islet allograft models <xref rid="bib0960" ref-type="bibr">[192]</xref>. TIM 3 signalling is suggested to play a major role in regulating allograft tolerance by negatively regulating T-cell responses.</p>
        </sec>
      </sec>
    </sec>
    <sec id="sec0105">
      <label>3</label>
      <title>Costimulatory blockade and the mixed chimerism approach</title>
      <p>As discussed earlier, blocking the CD28 and CD40 pathways has potent immonomodulating effects but does not induce robust tolerance by itself. The use of costimulation blockers as part of mixed chimerism protocols, however, turned out to be particularly effective in promoting tolerance in stringent rodent models. Establishment of mixed chimerism through transplantation of donor bone marrow (BM) is a promising strategy for inducing transplantation tolerance, achieving permanent acceptance of fully MHC mismatched skin grafts in the experimental setting (which is commonly regarded as the most stringent test for tolerance) <xref rid="bib0985" ref-type="bibr">[197]</xref> and operational tolerance in clinical renal transplantation <xref rid="bib0990 bib0995" ref-type="bibr">[198,199]</xref>. Widespread clinical application of this tolerance approach is, however, prevented by the toxicities of current BM transplantation (BMT) protocols. Since the introduction of the mixed chimerism concept with myeloablative total body irradiation (TBI) <xref rid="bib1000" ref-type="bibr">[200]</xref> and global T cell depletion <xref rid="bib1005 bib1010" ref-type="bibr">[201,202]</xref>, gradual progress has been made towards the development of minimally toxic conditioning regimens <xref rid="bib1015" ref-type="bibr">[203]</xref>. The introduction of costimulation blockers as a component of BMT protocols was a major step closer to this goal, allowing a drastic reduction of recipient conditioning by obviating the need for global destruction of the pre-existing recipient T cell repertoire <xref rid="bib1020 bib1025" ref-type="bibr">[204,205]</xref>. Subsequently, protocols devoid of recipient irradiation <xref rid="bib1030 bib1035" ref-type="bibr">[206,207]</xref> and even devoid of any cytotoxic conditioning became possible with the use of costimulation blockers <xref rid="bib1040" ref-type="bibr">[208]</xref>. Numerous such BMT protocols have since been developed, employing anti-CD154 mAbs with or without CTLA4Ig. In attempts to minimize cytotoxic recipient conditioning several adjunctive treatments were identified that promote BM engraftment under minimal conditioning in costimulation blocker-treated BMT recipients, including the use of facilitating cells, DST, non-depleting anti-CD4 and anti-CD8 mAbs, rapamycin, NK cell depletion and Treg treatment (reviewed in detail in <xref rid="bib1015 bib1045" ref-type="bibr">[203,209]</xref>).</p>
      <p>Central clonal deletion was recognized as a cardinal tolerance mechanism in mixed chimerism a long time ago and has remained a key mechanism also in protocols using costimulation blockers <xref rid="bib1050" ref-type="bibr">[210]</xref>. Since costimulation blockers allow BMT in recipients in which the pre-existing T cell repertoire was for the first time left largely intact, mechanisms of peripheral tolerance need to effectively control mature donor-reactive T cells in these systems. Progressive peripheral clonal deletion of mature donor-reactive CD4 <xref rid="bib1055" ref-type="bibr">[211]</xref> and CD8 <xref rid="bib1060" ref-type="bibr">[212]</xref> T cells was identified as the main mechanism of peripheral tolerance in such chimeras <xref rid="bib1025 bib1065" ref-type="bibr">[205,213]</xref>. Deletion shows features of both activation-induced cell death and passive cell death <xref rid="bib1065" ref-type="bibr">[213]</xref>, but the molecular details of this powerful tolerance mechanism that clonally eliminates mature donor-reactive T cells remain incompletely understood to this day. PD-1/PD-L1 is essential for CD8 but not CD4 T cell tolerance <xref rid="bib1070" ref-type="bibr">[214]</xref> as cell intrinsic PD-1 and either CTLA4 or B7-1/2 are required by CD8 (but not CD4) T cells <xref rid="bib1075" ref-type="bibr">[215]</xref>. While CD28 signalling is not required for tolerance induction in this model, an early cell intrinsic CTLA4 signal is critical for CD4 tolerance <xref rid="bib1080" ref-type="bibr">[216]</xref>. Non-deletional, regulatory mechanisms also contribute to peripheral tolerance <xref rid="bib1085" ref-type="bibr">[217]</xref>, but their relative importance depends on the degree of recipient conditioning, with regulation becoming more important with minimal conditioning <xref rid="bib1040 bib1090 bib1095" ref-type="bibr">[208,218,219]</xref>.</p>
      <p>The induction of chimerism and tolerance is markedly more difficult to achieve in large animals/NHP than in rodents, requiring more extensive recipient conditioning. In a DLI-identical canine BMT model, CTLA4Ig <xref rid="bib1100" ref-type="bibr">[220]</xref> and anti-CD154 mAb (together with DST) <xref rid="bib1105" ref-type="bibr">[221]</xref> improved BM engraftment, allowing the dose of total body irradiation to be reduced (tolerance was not tested). In an irradiation-based non-myeloablative NHP model of kidney allograft tolerance, adjunctive anti-CD154 mAb treatment enhanced chimerism and obviated the need for splenectomy, but did not obviate the need for T cell depletion <xref rid="bib1110" ref-type="bibr">[222]</xref>. Of note, while stable chimerism is necessary for the induction of skin graft tolerance in mice, transient chimerism in combination with kidney transplantation is sufficient to promote renal allograft tolerance in certain NHP systems <xref rid="bib1110 bib1115 bib1120" ref-type="bibr">[222–224]</xref> and in patients <xref rid="bib0995 bib1125" ref-type="bibr">[199,225]</xref>, indicating that the tolerance mechanisms differ significantly between these two settings. This difference might be explained at least in part through the fact that the kidney graft itself seems to participate in tolerance induction in NHP and humans <xref rid="bib1130" ref-type="bibr">[226]</xref>. In another NHP BMT model employing non-myeloablative doses of busulfan, costimulation blockade with anti-CD154 mAb plus belatacept, together with basiliximab and sirolimus, led to remarkably high levels of chimerism and a median chimerism duration of &gt;4 months (no organ transplants were preformed in this study) <xref rid="bib1135" ref-type="bibr">[227]</xref>. More recently, new MHC typing technologies became available in this rhesus macaque model allowing the investigation of defined MHC barriers <xref rid="bib1140" ref-type="bibr">[228]</xref>. Unexpectedly, donor BM was rejected after withdrawal of immunosuppression/costimulation blockade even in the MHC-matched situation (and also in the one haplotype-mismatched setting). Pre-existing non-tolerized donor-reactive T cells appear to be mainly responsible for BM rejection, although the mechanisms of this resistance towards costimulation blockade and mixed chimerism remain undefined. As no organs were transplanted, it is unclear whether or not operational tolerance towards a kidney graft would have been achieved with this regimen inducing transient chimerism. Thus, costimulation blockers are effective in large animal models of mixed chimerism, but considerably less so than in rodent models, necessitating more extensive recipient conditioning.</p>
    </sec>
    <sec id="sec0110">
      <label>4</label>
      <title>Clinical translation of costimulatory blockade</title>
      <p>Once it became apparent in the NHP setting that costimulation blockade does not induce tolerance by itself, attention shifted to employing costimulation blockers as immunosuppressive drug therapy. As mentioned earlier, development of anti-CD40L mAbs had to be stopped due to thromboembolic events and no data are yet available for the clinical use of anti-CD40 mAbs as possible alternative. Similarly, efalizumab (anti-LFA), which had been approved for the treatment of psoriasis, is no longer on the market. Thus, belatacept is currently the only costimulation blocker in an advanced stage of clinical development for use in organ transplant recipients.</p>
      <p>Results from phase II and phase III renal transplant trials have been reported with belatacept <xref rid="bib0180 bib0185 bib1145 bib1150 bib1155" ref-type="bibr">[36,37,229–231]</xref>. Collectively, the obtained data demonstrate that belatacept is effective as primary immunosuppressant (i.e. it does not require concomitant use of calcineurin inhibitors). Graft and patient survival in belatacept patients were comparable to those receiving cyclosporine. Notably, renal function at 1 and 2 years post-transplant was significantly better with belatacept compared to cyclosporine. However, episodes of acute rejection were more frequent in belatacept patients. Paradoxically, the incidence of acute rejection was higher in the group treated with a higher dose of belatacept than in the one treated with a lower dose (two dosing regimens were compared) <xref rid="bib0185" ref-type="bibr">[37]</xref>. While the specific cause for these observations is presently unknown, the current understanding of the complexities of the CD28/B7 pathway offers some potential explanations. It is conceivable that at higher concentrations B7 occupation by belatacept reaches a level that interferes with inhibitory signals through CTLA4 and/or PDL-1 which are important regulatory mechanisms fostering graft acceptance <xref rid="bib0025 bib0315 bib0775 bib1160" ref-type="bibr">[5,63,155,232]</xref>. Moreover, T regulatory cells might be impeded twofold, through the abrogation of CD28 signals and the inhibition of CTLA4 function. As CD28 signals suppress Th17 differentiation, CD28 blockade through belatacept might also drive Th17 development <xref rid="bib1165" ref-type="bibr">[233]</xref>. Regarding safety aspects, the side effects of belatacept were limited to the immune system without off-target toxicities, which are a major morbidity factor with calcineurin inhibitors. Like any non-specific immunosuppression, however, belatacept was associated with increased risks of infections and tumors. Of particular concern is the high incidence of post-transplant lymphoproliferative disorders (PTLD), including an unusually high number of cases with CNS involvement, that was observed with belatacept, in particular in Epstein–Barr virus serology negative recipients <xref rid="bib0185" ref-type="bibr">[37]</xref>.</p>
      <p>Thus, it is hoped that the costimulation blocker Belatacept will be approved as an immunosuppressant for use in kidney transplantation. The FDA however has expressed concerns about the high incidence of vascular rejection and occurrence of PTLD especially in the brain and thus has delayed its decision until clinical data at 3 years is presented. Despite these concerns the advantages of the use of this agent will hopefully allow approval which will reduce the dependence on CNI use. It remains to be seen whether belatacept-based protocols – likely involving additional biologicals <xref rid="bib0260" ref-type="bibr">[52]</xref> – can be developed which allow minimization or even controlled withdrawal of immunosuppression.</p>
    </sec>
    <sec id="sec0115">
      <label>5</label>
      <title>Conclusion</title>
      <p>It is firmly established that costimulatory signals are critical for the regulation of allo-immune responses and that their modulation represents a potent tool for preventing allograft rejection and potentially even for the induction of tolerance. However, recent advances in the field revealed that costimulation pathways are a complex network of numerous positive and negative, time-dependent and partially redundant signals whose effect also depends on the specific subset of T cells they affect. Although the therapeutic exploitation of costimulation blockade has consequently become more difficult to realize than initially envisioned, the costimulation blocker CTLA4Ig/belatacept is close to clinical approval as immunosuppressive drug and offers hope that other biologicals modulating T cell costimulation will follow.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib0005">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamb</surname>
              <given-names>K.E.</given-names>
            </name>
            <name>
              <surname>Lodhi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Meier-Kriesche</surname>
              <given-names>H.U.</given-names>
            </name>
          </person-group>
          <article-title>Long-term renal allograft survival in the United States: a critical reappraisal</article-title>
          <source>Am J Transplant</source>
          <volume>11</volume>
          <year>2010</year>
          <fpage>450</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">20973913</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenberg</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Mizuochi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sharrow</surname>
              <given-names>S.O.</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection</article-title>
          <source>J Exp Med</source>
          <volume>165</volume>
          <year>1987</year>
          <fpage>1296</fpage>
          <lpage>1315</lpage>
          <pub-id pub-id-type="pmid">2437237</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lafferty</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>A new analysis of allogeneic interactions</article-title>
          <source>Aust J Exp Biol Med Sci</source>
          <volume>53</volume>
          <year>1975</year>
          <fpage>27</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">238498</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jenkins</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo</article-title>
          <source>J Exp Med</source>
          <volume>165</volume>
          <year>1987</year>
          <fpage>302</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="pmid">3029267</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X.C.</given-names>
            </name>
            <name>
              <surname>Rothstein</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Sayegh</surname>
              <given-names>M.H.</given-names>
            </name>
          </person-group>
          <article-title>Costimulatory pathways in transplantation: challenges and new developments</article-title>
          <source>Immunol Rev</source>
          <volume>229</volume>
          <year>2009</year>
          <fpage>271</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="pmid">19426228</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sayegh</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Turka</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>The role of T-cell costimulatory activation pathways in transplant rejection</article-title>
          <source>N Engl J Med</source>
          <volume>338</volume>
          <year>1998</year>
          <fpage>1813</fpage>
          <lpage>1821</lpage>
          <pub-id pub-id-type="pmid">9632449</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pree</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>New approaches to prevent transplant rejection: co-stimulation blockers anti-CD40L and CTLA4Ig</article-title>
          <source>Drug Discov Today</source>
          <volume>3</volume>
          <year>2006</year>
          <fpage>41</fpage>
          <lpage>47</lpage>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mueller</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms maintaining peripheral tolerance</article-title>
          <source>Nat Immunol</source>
          <volume>11</volume>
          <year>2010</year>
          <fpage>21</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">20016506</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0045">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bigenzahn</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of transplant tolerance induction using costimulatory blockade</article-title>
          <source>Curr Opin Immunol</source>
          <volume>14</volume>
          <year>2002</year>
          <fpage>592</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="pmid">12183158</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0050">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Elwood</surname>
              <given-names>E.T.</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>D.Z.</given-names>
            </name>
            <name>
              <surname>Ritchie</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Hendrix</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tucker-Burden</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwys</article-title>
          <source>Nature</source>
          <volume>381</volume>
          <year>1996</year>
          <fpage>434</fpage>
          <lpage>438</lpage>
          <pub-id pub-id-type="pmid">8632801</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0055">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sayegh</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>X.G.</given-names>
            </name>
            <name>
              <surname>Magee</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Turka</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients</article-title>
          <source>Transplantation</source>
          <volume>64</volume>
          <year>1997</year>
          <fpage>1646</fpage>
          <lpage>1650</lpage>
          <pub-id pub-id-type="pmid">9422396</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0060">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirk</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Harlan</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>N.N.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>G.S.</given-names>
            </name>
          </person-group>
          <article-title>CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>94</volume>
          <year>1997</year>
          <fpage>8789</fpage>
          <lpage>8794</lpage>
          <pub-id pub-id-type="pmid">9238056</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0065">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirk</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Burkly</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Batty</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Baumgartner</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Berning</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Buchanan</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates</article-title>
          <source>Nat Med</source>
          <volume>5</volume>
          <year>1999</year>
          <fpage>686</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="pmid">10371508</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0070">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Tadaki</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Elster</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Burkly</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Berning</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Cruzata</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates</article-title>
          <source>Transplantation</source>
          <volume>74</volume>
          <year>2002</year>
          <fpage>940</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="pmid">12394834</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0075">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kean</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Gangappa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Transplant tolerance in non-human primates: progress, current challenges and unmet needs</article-title>
          <source>Am J Transplant</source>
          <volume>6</volume>
          <year>2006</year>
          <fpage>884</fpage>
          <lpage>893</lpage>
          <pub-id pub-id-type="pmid">16611324</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0080">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Knechtle</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kirk</surname>
              <given-names>A.D.</given-names>
            </name>
          </person-group>
          <article-title>A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression</article-title>
          <source>Am J Transplant</source>
          <volume>6</volume>
          <year>2006</year>
          <fpage>876</fpage>
          <lpage>883</lpage>
          <pub-id pub-id-type="pmid">16611323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0085">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valujskikh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pantenburg</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Heeger</surname>
              <given-names>P.S.</given-names>
            </name>
          </person-group>
          <article-title>Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice</article-title>
          <source>Am J Transplant</source>
          <volume>2</volume>
          <year>2002</year>
          <fpage>501</fpage>
          <lpage>509</lpage>
          <pub-id pub-id-type="pmid">12118893</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0090">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ford</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Translating costimulation blockade to the clinic: lessons learned from three pathways</article-title>
          <source>Immunol Rev</source>
          <volume>229</volume>
          <year>2009</year>
          <fpage>294</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">19426229</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0095">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paterson</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Vanguri</surname>
              <given-names>V.K.</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>SnapShot: B7/CD28 costimulation</article-title>
          <source>Cell</source>
          <volume>137</volume>
          <year>2009</year>
          <fpage>974</fpage>
          <lpage>1974</lpage>
          <pub-id pub-id-type="pmid">19490900</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0100">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salomon</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bluestone</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation</article-title>
          <source>Annu Rev Immunol</source>
          <volume>19</volume>
          <year>2001</year>
          <fpage>225</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="pmid">11244036</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0105">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenwald</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>The B7 family revisited</article-title>
          <source>Annu Rev Immunol</source>
          <volume>23</volume>
          <year>2005</year>
          <fpage>515</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="pmid">15771580</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0110">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halloran</surname>
              <given-names>P.F.</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppressive drugs for kidney transplantation</article-title>
          <source>N Engl J Med</source>
          <volume>351</volume>
          <year>2004</year>
          <fpage>2715</fpage>
          <lpage>2729</lpage>
          <pub-id pub-id-type="pmid">15616206</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0115">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>A cell culture model for T lymphocyte clonal anergy</article-title>
          <source>Science (New York, NY)</source>
          <volume>248</volume>
          <year>1990</year>
          <fpage>1349</fpage>
          <lpage>1356</lpage>
        </element-citation>
      </ref>
      <ref id="bib0120">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>T cell anergy</article-title>
          <source>Annu Rev Immunol</source>
          <volume>21</volume>
          <year>2003</year>
          <fpage>305</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="pmid">12471050</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0125">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walunas</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Lenschow</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Bakker</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>CTLA-4 can function as a negative regulator of T cell activation</article-title>
          <source>Immunity</source>
          <volume>1</volume>
          <year>1994</year>
          <fpage>405</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">7882171</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0130">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>The emerging role of CTLA-4 as an immune attenuator</article-title>
          <source>Immunity</source>
          <volume>7</volume>
          <year>1997</year>
          <fpage>445</fpage>
          <lpage>450</lpage>
          <pub-id pub-id-type="pmid">9354465</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0135">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakaguchi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Setoguchi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yagi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hori</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fehervari</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease</article-title>
          <source>Immunol Rev</source>
          <volume>212</volume>
          <year>2006</year>
          <fpage>8</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">16903903</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0140">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wing</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Onishi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Prieto-Martin</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Miyara</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fehervari</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>CTLA-4 control over Foxp3+ regulatory T cell function</article-title>
          <source>Science (New York, NY)</source>
          <volume>322</volume>
          <year>2008</year>
          <fpage>271</fpage>
          <lpage>275</lpage>
        </element-citation>
      </ref>
      <ref id="bib0145">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oderup</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cederbom</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Makowska</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cilio</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Ivars</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression</article-title>
          <source>Immunology</source>
          <volume>118</volume>
          <year>2006</year>
          <fpage>240</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="pmid">16771859</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0150">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grohmann</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Orabona</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fallarino</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Vacca</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Calcinaro</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Falorni</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>CTLA-4-Ig regulates tryptophan catabolism in vivo</article-title>
          <source>Nat Immunol</source>
          <volume>3</volume>
          <year>2002</year>
          <fpage>1097</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="pmid">12368911</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0155">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Ledbetter</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule</article-title>
          <source>Science (New York, NY)</source>
          <volume>257</volume>
          <year>1992</year>
          <fpage>792</fpage>
          <lpage>795</lpage>
        </element-citation>
      </ref>
      <ref id="bib0160">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Bajorath</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ledbetter</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Peach</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors</article-title>
          <source>Immunity</source>
          <volume>1</volume>
          <year>1994</year>
          <fpage>793</fpage>
          <lpage>801</lpage>
          <pub-id pub-id-type="pmid">7534620</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0165">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bluestone</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>St Clair</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Turka</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>CTLA4Ig: bridging the basic immunology with clinical application</article-title>
          <source>Immunity</source>
          <volume>24</volume>
          <year>2006</year>
          <fpage>233</fpage>
          <lpage>238</lpage>
          <pub-id pub-id-type="pmid">16546089</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0170">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kremer</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Westhovens</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Di Giorgio</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Alten</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Steinfeld</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig</article-title>
          <source>N Engl J Med</source>
          <volume>349</volume>
          <year>2003</year>
          <fpage>1907</fpage>
          <lpage>1915</lpage>
          <pub-id pub-id-type="pmid">14614165</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0175">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Tso</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Shirasugi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Strobert</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties</article-title>
          <source>Am J Transplant</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>443</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="pmid">15707398</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0180">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Durrbach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nashan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Blancho</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Costimulation blockade with belatacept in renal transplantation</article-title>
          <source>N Engl J Med</source>
          <volume>353</volume>
          <year>2005</year>
          <fpage>770</fpage>
          <lpage>781</lpage>
          <pub-id pub-id-type="pmid">16120857</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0185">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Charpentier</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Vanrenterghem</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Rostaing</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bresnahan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Darji</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)</article-title>
          <source>Am J Transplant</source>
          <volume>10</volume>
          <year>2010</year>
          <fpage>535</fpage>
          <lpage>546</lpage>
          <pub-id pub-id-type="pmid">20415897</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0190">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirk</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Tadaki</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Celniker</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Batty</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Berning</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>J.O.</given-names>
            </name>
          </person-group>
          <article-title>Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates</article-title>
          <source>Transplantation</source>
          <volume>72</volume>
          <year>2001</year>
          <fpage>377</fpage>
          <lpage>384</lpage>
          <pub-id pub-id-type="pmid">11502964</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0195">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Birsan</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hausen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Hubble</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Klupp</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stalder</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys</article-title>
          <source>Transplantation</source>
          <volume>75</volume>
          <year>2003</year>
          <fpage>2106</fpage>
          <lpage>2113</lpage>
          <pub-id pub-id-type="pmid">12829920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0200">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>What's in the pipeline? New immunosuppressive drugs in transplantation</article-title>
          <source>Am J Transplant</source>
          <volume>2</volume>
          <year>2002</year>
          <fpage>898</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="pmid">12482141</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0205">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perez</surname>
              <given-names>V.L.</given-names>
            </name>
            <name>
              <surname>Van Parijs</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Biuckians</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>X.X.</given-names>
            </name>
            <name>
              <surname>Strom</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>A.K.</given-names>
            </name>
          </person-group>
          <article-title>Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement</article-title>
          <source>Immunity</source>
          <volume>6</volume>
          <year>1997</year>
          <fpage>411</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">9133420</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0210">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>D.Z.</given-names>
            </name>
            <name>
              <surname>Winn</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Lowry</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Transplantation tolerance induced by CTLA4-Ig</article-title>
          <source>Transplantation</source>
          <volume>57</volume>
          <year>1994</year>
          <fpage>1701</fpage>
          <lpage>1706</lpage>
          <pub-id pub-id-type="pmid">8016872</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0215">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bolling</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>R.Q.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>C.B.</given-names>
            </name>
          </person-group>
          <article-title>Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion</article-title>
          <source>J Exp Med</source>
          <volume>178</volume>
          <year>1993</year>
          <fpage>1801</fpage>
          <lpage>1806</lpage>
          <pub-id pub-id-type="pmid">8228826</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0220">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baliga</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chavin</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Woodward</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
          </person-group>
          <article-title>CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity</article-title>
          <source>Transplantation</source>
          <volume>58</volume>
          <year>1994</year>
          <fpage>1082</fpage>
          <lpage>1090</lpage>
          <pub-id pub-id-type="pmid">7526493</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0225">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turka</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Linsley</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Leiden</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>R.Q.</given-names>
            </name>
          </person-group>
          <article-title>T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>89</volume>
          <year>1992</year>
          <fpage>11102</fpage>
          <lpage>11105</lpage>
          <pub-id pub-id-type="pmid">1332070</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0230">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lenschow</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Thistlethwaite</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Montag</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg</article-title>
          <source>Science (New York, NY)</source>
          <volume>257</volume>
          <year>1992</year>
          <fpage>789</fpage>
          <lpage>792</lpage>
        </element-citation>
      </ref>
      <ref id="bib0235">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Azuma</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Chandraker</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Nadeau</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Tilney</surname>
              <given-names>N.L.</given-names>
            </name>
          </person-group>
          <article-title>Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>93</volume>
          <year>1996</year>
          <fpage>12439</fpage>
          <lpage>12444</lpage>
          <pub-id pub-id-type="pmid">8901600</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0240">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandraker</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Azuma</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nadeau</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Tilney</surname>
              <given-names>N.L.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>W.W.</given-names>
            </name>
          </person-group>
          <article-title>Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection</article-title>
          <source>J Clin Invest</source>
          <volume>101</volume>
          <year>1998</year>
          <fpage>2309</fpage>
          <lpage>2318</lpage>
          <pub-id pub-id-type="pmid">9616202</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0245">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavinato</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Casiraghi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Azzollini</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cassis</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cugini</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mister</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells</article-title>
          <source>Transplantation</source>
          <volume>79</volume>
          <year>2005</year>
          <fpage>1034</fpage>
          <lpage>1039</lpage>
          <pub-id pub-id-type="pmid">15880039</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0250">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Judge</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spain</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Deans-Gratiot</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sayegh</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Turka</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>The in vivo mechanism of action of CTLA4Ig</article-title>
          <source>J Immunol</source>
          <volume>156</volume>
          <year>1996</year>
          <fpage>2294</fpage>
          <lpage>2299</lpage>
          <pub-id pub-id-type="pmid">8690920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0255">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levisetti</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Padrid</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Szot</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Mittal</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Meehan</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Wardrip</surname>
              <given-names>C.L.</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation</article-title>
          <source>J Immunol</source>
          <volume>159</volume>
          <year>1997</year>
          <fpage>5187</fpage>
          <lpage>5191</lpage>
          <pub-id pub-id-type="pmid">9548454</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0260">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weaver</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Charafeddine</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Leopardi</surname>
              <given-names>F.V.</given-names>
            </name>
          </person-group>
          <article-title>Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates</article-title>
          <source>Nat Med</source>
          <volume>15</volume>
          <year>2009</year>
          <fpage>746</fpage>
          <lpage>749</lpage>
          <pub-id pub-id-type="pmid">19584865</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0265">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Weaver</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Stempora</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Selective targeting of human alloresponsive CD8<sup>+</sup> effector memory T cells based on CD2 expression</article-title>
          <source>Am J Transplant</source>
          <volume>11</volume>
          <year>2011</year>
          <fpage>22</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">21070604</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0270">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poirier</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Blancho</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vanhove</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>A more selective costimulatory blockade of the CD28–B7 pathway</article-title>
          <source>Transpl Int</source>
          <volume>24</volume>
          <year>2011</year>
          <fpage>2</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">20964725</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0275">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Hunig</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist</article-title>
          <source>Eur J Immunol</source>
          <volume>33</volume>
          <year>2003</year>
          <fpage>626</fpage>
          <lpage>638</lpage>
          <pub-id pub-id-type="pmid">12616483</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0280">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunig</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies</article-title>
          <source>Adv Immunol</source>
          <volume>95</volume>
          <year>2007</year>
          <fpage>111</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="pmid">17869612</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0285">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beyersdorf</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gaupp</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Balbach</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Toyka</surname>
              <given-names>K.V.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>C.H.</given-names>
            </name>
          </person-group>
          <article-title>Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis</article-title>
          <source>J Exp Med</source>
          <volume>202</volume>
          <year>2005</year>
          <fpage>445</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="pmid">16061730</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0290">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beyersdorf</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Hunig</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kerkau</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease</article-title>
          <source>Blood</source>
          <volume>114</volume>
          <year>2009</year>
          <fpage>4575</fpage>
          <lpage>4582</lpage>
          <pub-id pub-id-type="pmid">19721011</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0295">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haspot</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Seveno</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dugast</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Coulon</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Renaudin</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Usal</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells</article-title>
          <source>Am J Transplant</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>2339</fpage>
          <lpage>2348</lpage>
          <pub-id pub-id-type="pmid">16162181</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0300">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laskowski</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Pratschke</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wilhelm</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Beato</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Taal</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats</article-title>
          <source>J Am Soc Nephrol</source>
          <volume>13</volume>
          <year>2002</year>
          <fpage>519</fpage>
          <lpage>527</lpage>
          <pub-id pub-id-type="pmid">11805183</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0305">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suntharalingam</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brett</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Castello-Cortes</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412</article-title>
          <source>N Engl J Med</source>
          <volume>355</volume>
          <year>2006</year>
          <fpage>1018</fpage>
          <lpage>1028</lpage>
          <pub-id pub-id-type="pmid">16908486</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0310">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gogishvili</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Langenhorst</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Luhder</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Elflein</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dennehy</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice</article-title>
          <source>PLoS One</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>e4643</fpage>
          <pub-id pub-id-type="pmid">19247496</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0315">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poirier</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Azimzadeh</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Dilek</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mary</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation</article-title>
          <source>Sci Transl Med</source>
          <year>2010</year>
          <fpage>2</fpage>
        </element-citation>
      </ref>
      <ref id="bib0320">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hutloff</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dittrich</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Eljaschewitsch</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kraft</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Anagnostopoulos</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28</article-title>
          <source>Nature</source>
          <volume>397</volume>
          <year>1999</year>
          <fpage>263</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">9930702</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0325">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coyle</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Lehar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Delaney</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Manning</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>The CD28-related molecule ICOS is required for effective T cell-dependent immune responses</article-title>
          <source>Immunity</source>
          <volume>13</volume>
          <year>2000</year>
          <fpage>95</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="pmid">10933398</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0330">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okazaki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Honjo</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>New regulatory co-receptors: inducible co-stimulator and PD-1</article-title>
          <source>Curr Opin Immunol</source>
          <volume>14</volume>
          <year>2002</year>
          <fpage>779</fpage>
          <lpage>782</lpage>
          <pub-id pub-id-type="pmid">12413529</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0335">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tafuri</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shahinian</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bladt</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Yoshinaga</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Jordana</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wakeham</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>ICOS is essential for effective T-helper-cell responses</article-title>
          <source>Nature</source>
          <volume>409</volume>
          <year>2001</year>
          <fpage>105</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">11343123</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0340">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richter</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hayden-Ledbetter</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Irgang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ledbetter</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Westermann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Korner</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells</article-title>
          <source>J Biol Chem</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>45686</fpage>
          <lpage>45693</lpage>
          <pub-id pub-id-type="pmid">11571308</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0345">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Salama</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Sho</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Izawa</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sandner</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>The role of the ICOS–B7h T cell costimulatory pathway in transplantation immunity</article-title>
          <source>J Clin Invest</source>
          <volume>112</volume>
          <year>2003</year>
          <fpage>234</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="pmid">12865411</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0350">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Juedes</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Temann</surname>
              <given-names>U.A.</given-names>
            </name>
            <name>
              <surname>Shresta</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Ruddle</surname>
              <given-names>N.H.</given-names>
            </name>
          </person-group>
          <article-title>ICOS co-stimulatory receptor is essential for T-cell activation and function</article-title>
          <source>Nature</source>
          <volume>409</volume>
          <year>2001</year>
          <fpage>97</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="pmid">11343121</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0355">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kopf</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Barner</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oxenius</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gallimore</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection</article-title>
          <source>J Exp Med</source>
          <volume>192</volume>
          <year>2000</year>
          <fpage>53</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">10880526</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0360">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozkaynak</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Shemmeri</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gutierrez-Ramos</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Amaral</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Importance of ICOS–B7RP-1 costimulation in acute and chronic allograft rejection</article-title>
          <source>Nat Immunol</source>
          <volume>2</volume>
          <year>2001</year>
          <fpage>591</fpage>
          <lpage>596</lpage>
          <pub-id pub-id-type="pmid">11429542</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0365">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosuge</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gotoh</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Koga</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Isobe</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway</article-title>
          <source>Transplantation</source>
          <volume>75</volume>
          <year>2003</year>
          <fpage>1374</fpage>
          <lpage>1379</lpage>
          <pub-id pub-id-type="pmid">12717233</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0370">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
          </person-group>
          <article-title>The CD40 pathway in allograft rejection, acceptance, and tolerance</article-title>
          <source>Curr Opin Immunol</source>
          <volume>9</volume>
          <year>1997</year>
          <fpage>641</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="pmid">9368772</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0375">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Kooten</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Banchereau</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Functions of CD40 on B cells, dendritic cells and other cells</article-title>
          <source>Curr Opin Immunol</source>
          <volume>9</volume>
          <year>1997</year>
          <fpage>330</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="pmid">9203418</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0380">
        <label>76</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blair</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Harlan</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Abe</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tadaki</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis</article-title>
          <source>J Exp Med</source>
          <volume>191</volume>
          <year>2000</year>
          <fpage>651</fpage>
          <lpage>660</lpage>
          <pub-id pub-id-type="pmid">10684857</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0385">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waldmann</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The new immunosuppression: just kill the T cell</article-title>
          <source>Nat Med</source>
          <volume>9</volume>
          <year>2003</year>
          <fpage>1259</fpage>
          <lpage>1260</lpage>
          <pub-id pub-id-type="pmid">14520372</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0390">
        <label>78</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mai</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bucher</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bosco</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Andres</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Anti-CD154 mAb treatment but not recipient CD154 deficiency leads to long-term survival of xenogeneic islet grafts</article-title>
          <source>Am J Transplant</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>1021</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="pmid">15816882</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0395">
        <label>79</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shaffer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms involved in the establishment of tolerance through costimulatory blockade and BMT: lack of requirement for CD40L-mediated signaling for tolerance or deletion of donor-reactive CD4+ cells</article-title>
          <source>Am J Transplant</source>
          <volume>1</volume>
          <year>2001</year>
          <fpage>339</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="pmid">12099378</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0400">
        <label>80</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monk</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Hargreaves</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Marsh</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Farrar</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Sacks</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Millrain</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade</article-title>
          <source>Nat Med</source>
          <volume>9</volume>
          <year>2003</year>
          <fpage>1275</fpage>
          <lpage>1280</lpage>
          <pub-id pub-id-type="pmid">14502279</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0405">
        <label>81</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conley</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Larche</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bonagura</surname>
              <given-names>V.R.</given-names>
            </name>
            <name>
              <surname>Lawton</surname>
              <given-names>A.R.</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Hyper IgM syndrome associated with defective CD40-mediated B cell activation</article-title>
          <source>J Clin Invest</source>
          <volume>94</volume>
          <year>1994</year>
          <fpage>1404</fpage>
          <lpage>1409</lpage>
          <pub-id pub-id-type="pmid">7523449</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0410">
        <label>82</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Stunz</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Bishop</surname>
              <given-names>G.A.</given-names>
            </name>
          </person-group>
          <article-title>CD40 and autoimmunity: the dark side of a great activator</article-title>
          <source>Semin Immunol</source>
          <volume>21</volume>
          <year>2009</year>
          <fpage>293</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="pmid">19595612</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0415">
        <label>83</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quezada</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Jarvinen</surname>
              <given-names>L.Z.</given-names>
            </name>
            <name>
              <surname>Lind</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Noelle</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>CD40/CD154 interactions at the interface of tolerance and immunity</article-title>
          <source>Annu Rev Immunol</source>
          <volume>22</volume>
          <year>2004</year>
          <fpage>307</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="pmid">15032580</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0420">
        <label>84</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Schonbeck</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Mach</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>R.N.</given-names>
            </name>
          </person-group>
          <article-title>Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis</article-title>
          <source>J Immunol</source>
          <volume>165</volume>
          <year>2000</year>
          <fpage>3506</fpage>
          <lpage>3518</lpage>
          <pub-id pub-id-type="pmid">10975872</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0425">
        <label>85</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guillot</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Guillonneau</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gerdes</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Menoret</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Braudeau</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Prolonged blockade of CD40–CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection</article-title>
          <source>J Immunol</source>
          <volume>168</volume>
          <year>2002</year>
          <fpage>1600</fpage>
          <lpage>1609</lpage>
          <pub-id pub-id-type="pmid">11823487</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0430">
        <label>86</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Preston</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Tadaki</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Hale</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Harlan</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation</article-title>
          <source>J Immunol</source>
          <volume>170</volume>
          <year>2003</year>
          <fpage>2776</fpage>
          <lpage>2782</lpage>
          <pub-id pub-id-type="pmid">12594309</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0435">
        <label>87</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trambley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bingaman</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Elwood</surname>
              <given-names>E.T.</given-names>
            </name>
            <name>
              <surname>Waitze</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection</article-title>
          <source>J Clin Invest</source>
          <volume>104</volume>
          <year>1999</year>
          <fpage>1715</fpage>
          <lpage>1722</lpage>
          <pub-id pub-id-type="pmid">10606625</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0440">
        <label>88</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Trambley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Durham</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts</article-title>
          <source>J Immunol</source>
          <volume>165</volume>
          <year>2000</year>
          <fpage>6849</fpage>
          <lpage>6857</lpage>
          <pub-id pub-id-type="pmid">11120808</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0445">
        <label>89</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kenyon</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Masetti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ranuncoli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chatzipetrou</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154</article-title>
          <source>Diabetes</source>
          <volume>48</volume>
          <year>1999</year>
          <fpage>1473</fpage>
          <lpage>1481</lpage>
          <pub-id pub-id-type="pmid">10389857</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0450">
        <label>90</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sidiropoulos</surname>
              <given-names>P.I.</given-names>
            </name>
            <name>
              <surname>Boumpas</surname>
              <given-names>D.T.</given-names>
            </name>
          </person-group>
          <article-title>Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients</article-title>
          <source>Lupus</source>
          <volume>13</volume>
          <year>2004</year>
          <fpage>391</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="pmid">15230298</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0455">
        <label>91</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Colvin</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Sachs</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Cosimi</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand</article-title>
          <source>Nat Med</source>
          <volume>6</volume>
          <year>2000</year>
          <fpage>114</fpage>
        </element-citation>
      </ref>
      <ref id="bib0460">
        <label>92</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andre</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Denis</surname>
              <given-names>C.V.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Papalia</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Hynes</surname>
              <given-names>R.O.</given-names>
            </name>
          </person-group>
          <article-title>CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism</article-title>
          <source>Nat Med</source>
          <volume>8</volume>
          <year>2002</year>
          <fpage>247</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="pmid">11875495</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0465">
        <label>93</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Shirasugi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Durham</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Strobert</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Cowan</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival</article-title>
          <source>J Immunol</source>
          <volume>174</volume>
          <year>2005</year>
          <fpage>542</fpage>
          <lpage>550</lpage>
          <pub-id pub-id-type="pmid">15611281</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0470">
        <label>94</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilson</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Milas</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Gangappa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hollenbaugh</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation</article-title>
          <source>J Immunol</source>
          <volume>183</volume>
          <year>2009</year>
          <fpage>1625</fpage>
          <lpage>1635</lpage>
          <pub-id pub-id-type="pmid">19592649</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0475">
        <label>95</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gramaglia</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Lemon</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses</article-title>
          <source>J Immunol</source>
          <volume>161</volume>
          <year>1998</year>
          <fpage>6510</fpage>
          <lpage>6517</lpage>
          <pub-id pub-id-type="pmid">9862675</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0480">
        <label>96</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gramaglia</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Killeen</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells</article-title>
          <source>Immunity</source>
          <volume>15</volume>
          <year>2001</year>
          <fpage>445</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="pmid">11567634</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0485">
        <label>97</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stuber</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Strober</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>The T cell–B cell interaction via OX40–OX40L is necessary for the T cell-dependent humoral immune response</article-title>
          <source>J Exp Med</source>
          <volume>183</volume>
          <year>1996</year>
          <fpage>979</fpage>
          <lpage>989</lpage>
          <pub-id pub-id-type="pmid">8642301</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0490">
        <label>98</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Gulbranson-Judge</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brocker</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Raykundalia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Goodall</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers</article-title>
          <source>J Exp Med</source>
          <volume>190</volume>
          <year>1999</year>
          <fpage>1115</fpage>
          <lpage>1122</lpage>
          <pub-id pub-id-type="pmid">10523609</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0495">
        <label>99</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lane</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells</article-title>
          <source>J Exp Med</source>
          <volume>191</volume>
          <year>2000</year>
          <fpage>201</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">10637265</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0500">
        <label>100</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugamura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>A.D.</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40</article-title>
          <source>Nat Rev Immunol</source>
          <volume>4</volume>
          <year>2004</year>
          <fpage>420</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="pmid">15173831</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0505">
        <label>101</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Demirci</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Amanullah</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Kewalaramani</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yagita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Strom</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Sayegh</surname>
              <given-names>M.H.</given-names>
            </name>
          </person-group>
          <article-title>Critical role of OX40 in CD28 and CD154-independent rejection</article-title>
          <source>J Immunol</source>
          <volume>172</volume>
          <year>2004</year>
          <fpage>1691</fpage>
          <lpage>1698</lpage>
          <pub-id pub-id-type="pmid">14734751</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0510">
        <label>102</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuan</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Salama</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Najafian</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Chandraker</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The role of the CD134–CD134 ligand costimulatory pathway in alloimmune responses in vivo</article-title>
          <source>J Immunol</source>
          <volume>170</volume>
          <year>2003</year>
          <fpage>2949</fpage>
          <lpage>2955</lpage>
          <pub-id pub-id-type="pmid">12626546</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0515">
        <label>103</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dawicki</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Bertram</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses</article-title>
          <source>J Immunol</source>
          <volume>173</volume>
          <year>2004</year>
          <fpage>5944</fpage>
          <lpage>5951</lpage>
          <pub-id pub-id-type="pmid">15528328</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0520">
        <label>104</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gudmundsdottir</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Turka</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>A closer look at homeostatic proliferation of CD4+ T cells: costimulatory requirements and role in memory formation</article-title>
          <source>J Immunol</source>
          <volume>167</volume>
          <year>2001</year>
          <fpage>3699</fpage>
          <lpage>3707</lpage>
          <pub-id pub-id-type="pmid">11564785</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0525">
        <label>105</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bensinger</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>Homeostatic proliferation is a barrier to transplantation tolerance</article-title>
          <source>Nat Med</source>
          <volume>10</volume>
          <year>2004</year>
          <fpage>87</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">14647496</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0530">
        <label>106</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koehn</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gangappa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Patients, pathogens, and protective immunity: the relevance of virus-induced alloreactivity in transplantation</article-title>
          <source>J Immunol</source>
          <volume>176</volume>
          <year>2006</year>
          <fpage>2691</fpage>
          <lpage>2696</lpage>
          <pub-id pub-id-type="pmid">16493023</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0535">
        <label>107</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>So</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells</article-title>
          <source>J Immunol</source>
          <volume>179</volume>
          <year>2007</year>
          <fpage>1427</fpage>
          <lpage>1430</lpage>
          <pub-id pub-id-type="pmid">17641007</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0540">
        <label>108</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gri</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Piconese</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Frossi</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Manfroi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Merluzzi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tripodo</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40–OX40L interaction</article-title>
          <source>Immunity</source>
          <volume>29</volume>
          <year>2008</year>
          <fpage>771</fpage>
          <lpage>781</lpage>
          <pub-id pub-id-type="pmid">18993084</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0545">
        <label>109</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valzasina</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Guiducci</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dislich</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Killeen</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>M.P.</given-names>
            </name>
          </person-group>
          <article-title>Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR</article-title>
          <source>Blood</source>
          <volume>105</volume>
          <year>2005</year>
          <fpage>2845</fpage>
          <lpage>2851</lpage>
          <pub-id pub-id-type="pmid">15591118</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0550">
        <label>110</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vu</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Degauque</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kroemer</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>OX40 costimulation turns off Foxp3+ Tregs</article-title>
          <source>Blood</source>
          <volume>110</volume>
          <year>2007</year>
          <fpage>2501</fpage>
          <lpage>2510</lpage>
          <pub-id pub-id-type="pmid">17575071</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0555">
        <label>111</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ito</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.H.</given-names>
            </name>
            <name>
              <surname>Duramad</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Hanabuchi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Perng</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Gilliet</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>OX40 ligand shuts down IL-10-producing regulatory T cells</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>103</volume>
          <year>2006</year>
          <fpage>13138</fpage>
          <lpage>13143</lpage>
          <pub-id pub-id-type="pmid">16924108</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0560">
        <label>112</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Newell</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>The role of TNF receptor and TNF superfamily molecules in organ transplantation</article-title>
          <source>Am J Transplant</source>
          <volume>2</volume>
          <year>2002</year>
          <fpage>12</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="pmid">12095050</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0565">
        <label>113</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cannons</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ghumman</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>DeBenedette</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Yagita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy</article-title>
          <source>J Immunol</source>
          <volume>167</volume>
          <year>2001</year>
          <fpage>1313</fpage>
          <lpage>1324</lpage>
          <pub-id pub-id-type="pmid">11466348</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0570">
        <label>114</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vinay</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Role of 4-1BB in immune responses</article-title>
          <source>Semin Immunol</source>
          <volume>10</volume>
          <year>1998</year>
          <fpage>481</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="pmid">9826581</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0575">
        <label>115</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeBenedette</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bachmann</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Barber</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Stocking</surname>
              <given-names>K.L.</given-names>
            </name>
          </person-group>
          <article-title>Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus</article-title>
          <source>J Immunol</source>
          <volume>163</volume>
          <year>1999</year>
          <fpage>4833</fpage>
          <lpage>4841</lpage>
          <pub-id pub-id-type="pmid">10528184</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0580">
        <label>116</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cooper</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bansal-Pakala</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity</article-title>
          <source>Eur J Immunol</source>
          <volume>32</volume>
          <year>2002</year>
          <fpage>521</fpage>
          <lpage>529</lpage>
          <pub-id pub-id-type="pmid">11828369</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0585">
        <label>117</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Role of 4-1BB in allograft rejection mediated by CD8<sup>+</sup> T cells</article-title>
          <source>Am J Transplant</source>
          <volume>3</volume>
          <year>2003</year>
          <fpage>543</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="pmid">12752310</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0590">
        <label>118</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cho</surname>
              <given-names>H.R.</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Yagita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>La</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.E.</given-names>
            </name>
          </person-group>
          <article-title>Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival</article-title>
          <source>Transpl Int</source>
          <volume>17</volume>
          <year>2004</year>
          <fpage>351</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">15349720</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0595">
        <label>119</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ishida</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance</article-title>
          <source>Nat Immunol</source>
          <volume>3</volume>
          <year>2002</year>
          <fpage>135</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">11812990</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0600">
        <label>120</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durrbach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Francois</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Jacquet</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beaudreuil</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Charpentier</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Co-signals in organ transplantation</article-title>
          <source>Curr Opin Org Transplant</source>
          <volume>15</volume>
          <year>2010</year>
          <fpage>474</fpage>
          <lpage>480</lpage>
        </element-citation>
      </ref>
      <ref id="bib0605">
        <label>121</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanamaru</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Youngnak</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hashiguchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nishioka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells</article-title>
          <source>J Immunol</source>
          <volume>172</volume>
          <year>2004</year>
          <fpage>7306</fpage>
          <lpage>7314</lpage>
          <pub-id pub-id-type="pmid">15187106</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0610">
        <label>122</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gravestein</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Borst</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor receptor family members in the immune system</article-title>
          <source>Semin Immunol</source>
          <volume>10</volume>
          <year>1998</year>
          <fpage>423</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="pmid">9826575</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0615">
        <label>123</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ronchetti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zollo</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Bruscoli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Agostini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bianchini</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Nocentini</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations</article-title>
          <source>Eur J Immunol</source>
          <volume>34</volume>
          <year>2004</year>
          <fpage>613</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="pmid">14991590</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0620">
        <label>124</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolls</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>LFA-1 (CD11a) as a therapeutic target</article-title>
          <source>Am J Transplant</source>
          <volume>6</volume>
          <year>2006</year>
          <fpage>27</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="pmid">16433753</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0625">
        <label>125</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>LFA-1: more than just T cell Velcro</article-title>
          <source>Nat Immunol</source>
          <volume>4</volume>
          <year>2003</year>
          <fpage>1052</fpage>
          <lpage>1054</lpage>
          <pub-id pub-id-type="pmid">14586422</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0630">
        <label>126</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Seventer</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Horgan</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells</article-title>
          <source>J Immunol</source>
          <volume>144</volume>
          <year>1990</year>
          <fpage>4579</fpage>
          <lpage>4586</lpage>
          <pub-id pub-id-type="pmid">1972160</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0635">
        <label>127</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cai</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Brunmark</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Sprent</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8<sup>+</sup> T cells</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>93</volume>
          <year>1996</year>
          <fpage>14736</fpage>
          <lpage>14741</lpage>
          <pub-id pub-id-type="pmid">8962124</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0640">
        <label>128</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Owens</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>A role for adhesion molecules in contact-dependent T help for B cells</article-title>
          <source>Eur J Immunol</source>
          <volume>21</volume>
          <year>1991</year>
          <fpage>979</fpage>
          <lpage>983</lpage>
          <pub-id pub-id-type="pmid">1673435</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0645">
        <label>129</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanders</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Makgoba</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Sharrow</surname>
              <given-names>S.O.</given-names>
            </name>
            <name>
              <surname>Stephany</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Springer</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>H.A.</given-names>
            </name>
          </person-group>
          <article-title>Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production</article-title>
          <source>J Immunol</source>
          <volume>140</volume>
          <year>1988</year>
          <fpage>1401</fpage>
          <lpage>1407</lpage>
          <pub-id pub-id-type="pmid">2894392</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0650">
        <label>130</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Metzler</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gfeller</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bigaud</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wieczorek</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Heusser</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection</article-title>
          <source>J Immunol</source>
          <volume>173</volume>
          <year>2004</year>
          <fpage>7025</fpage>
          <lpage>7036</lpage>
          <pub-id pub-id-type="pmid">15557200</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0655">
        <label>131</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rayat</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB</article-title>
          <source>Diabetes</source>
          <volume>54</volume>
          <year>2005</year>
          <fpage>443</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="pmid">15677502</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0660">
        <label>132</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolls</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Coulombe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bolwerk</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4</article-title>
          <source>J Immunol</source>
          <volume>164</volume>
          <year>2000</year>
          <fpage>3627</fpage>
          <lpage>3634</lpage>
          <pub-id pub-id-type="pmid">10725719</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0665">
        <label>133</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isobe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yagita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ihara</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1</article-title>
          <source>Science (New York, NY)</source>
          <volume>255</volume>
          <year>1992</year>
          <fpage>1125</fpage>
          <lpage>1127</lpage>
        </element-citation>
      </ref>
      <ref id="bib0670">
        <label>134</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isobe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sekiguchi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice</article-title>
          <source>Transplantation</source>
          <volume>62</volume>
          <year>1996</year>
          <fpage>411</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">8779692</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0675">
        <label>135</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blazar</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Panoskaltsis-Mortari</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Vallera</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts</article-title>
          <source>Blood</source>
          <volume>85</volume>
          <year>1995</year>
          <fpage>2607</fpage>
          <lpage>2618</lpage>
          <pub-id pub-id-type="pmid">7537122</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0680">
        <label>136</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maraninchi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mawas</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Stoppa</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Gaspard</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Marit</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Van Ekthoven</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults</article-title>
          <source>Bone Marrow Transplant</source>
          <volume>4</volume>
          <year>1989</year>
          <fpage>147</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">2650783</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0685">
        <label>137</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hourmant</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bedrossian</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Durand</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lebranchu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Renoult</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Caudrelier</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations</article-title>
          <source>Transplantation</source>
          <volume>62</volume>
          <year>1996</year>
          <fpage>1565</fpage>
          <lpage>1570</lpage>
          <pub-id pub-id-type="pmid">8970608</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0690">
        <label>138</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Pescovitz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rajagopalan</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Butt</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation</article-title>
          <source>Am J Transplant</source>
          <volume>7</volume>
          <year>2007</year>
          <fpage>1770</fpage>
          <lpage>1777</lpage>
          <pub-id pub-id-type="pmid">17564637</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0695">
        <label>139</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stern</surname>
              <given-names>R.S.</given-names>
            </name>
          </person-group>
          <article-title>A promising step forward in psoriasis therapy</article-title>
          <source>JAMA</source>
          <volume>290</volume>
          <year>2003</year>
          <fpage>3133</fpage>
          <lpage>3135</lpage>
          <pub-id pub-id-type="pmid">14679277</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0700">
        <label>140</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dedrick</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Walicke</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Garovoy</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody</article-title>
          <source>Transpl Immunol</source>
          <volume>9</volume>
          <year>2002</year>
          <fpage>181</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">12180828</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0705">
        <label>141</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebwohl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tyring</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Toth</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tawfik</surname>
              <given-names>N.H.</given-names>
            </name>
          </person-group>
          <article-title>A novel targeted T-cell modulator, efalizumab, for plaque psoriasis</article-title>
          <source>N Engl J Med</source>
          <volume>349</volume>
          <year>2003</year>
          <fpage>2004</fpage>
          <lpage>2013</lpage>
          <pub-id pub-id-type="pmid">14627785</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0710">
        <label>142</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poston</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Simms</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Presta</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Jardieu</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients</article-title>
          <source>Transplantation</source>
          <volume>69</volume>
          <year>2000</year>
          <fpage>2005</fpage>
          <lpage>2013</lpage>
          <pub-id pub-id-type="pmid">10852588</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0715">
        <label>143</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Badell</surname>
              <given-names>I.R.</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>P.W.</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Weaver</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>LFA-1-specific therapy prolongs allograft survival in rhesus macaques</article-title>
          <source>J Clin Invest</source>
          <volume>120</volume>
          <year>2010</year>
          <fpage>4520</fpage>
          <lpage>4531</lpage>
          <pub-id pub-id-type="pmid">21099108</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0720">
        <label>144</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collins</surname>
              <given-names>A.V.</given-names>
            </name>
            <name>
              <surname>Brodie</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Iaboni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Manso-Sancho</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Walse</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>The interaction properties of costimulatory molecules revisited</article-title>
          <source>Immunity</source>
          <volume>17</volume>
          <year>2002</year>
          <fpage>201</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="pmid">12196291</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0725">
        <label>145</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wing</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Regulatory T</surname>
            </name>
          </person-group>
          <article-title>cells exert checks and balances on self tolerance and autoimmunity</article-title>
          <source>Nat Immunol</source>
          <volume>11</volume>
          <year>2010</year>
          <fpage>7</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">20016504</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0730">
        <label>146</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jago</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Yates</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Camara</surname>
              <given-names>N.O.</given-names>
            </name>
            <name>
              <surname>Lechler</surname>
              <given-names>R.I.</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Differential expression of CTLA-4 among T cell subsets</article-title>
          <source>Clin Exp Immunol</source>
          <volume>136</volume>
          <year>2004</year>
          <fpage>463</fpage>
          <lpage>471</lpage>
          <pub-id pub-id-type="pmid">15147348</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0735">
        <label>147</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krummel</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation</article-title>
          <source>J Exp Med</source>
          <volume>182</volume>
          <year>1995</year>
          <fpage>459</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="pmid">7543139</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0740">
        <label>148</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waterhouse</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Penninger</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Timms</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wakeham</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shahinian</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>K.P.</given-names>
            </name>
          </person-group>
          <article-title>Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4</article-title>
          <source>Science (New York, NY)</source>
          <volume>270</volume>
          <year>1995</year>
          <fpage>985</fpage>
          <lpage>988</lpage>
        </element-citation>
      </ref>
      <ref id="bib0745">
        <label>149</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tivol</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Boyd</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>McKeon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Borriello</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Nickerson</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Strom</surname>
              <given-names>T.B.</given-names>
            </name>
          </person-group>
          <article-title>CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice</article-title>
          <source>J Immunol</source>
          <volume>158</volume>
          <year>1997</year>
          <fpage>5091</fpage>
          <lpage>5094</lpage>
          <pub-id pub-id-type="pmid">9164923</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0750">
        <label>150</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandelbrot</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>McAdam</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)</article-title>
          <source>J Exp Med</source>
          <volume>189</volume>
          <year>1999</year>
          <fpage>435</fpage>
          <lpage>440</lpage>
          <pub-id pub-id-type="pmid">9892625</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0755">
        <label>151</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hwang</surname>
              <given-names>K.W.</given-names>
            </name>
            <name>
              <surname>Sweatt</surname>
              <given-names>W.B.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>I.E.</given-names>
            </name>
            <name>
              <surname>Blank</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gajewski</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Bluestone</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells</article-title>
          <source>J Immunol</source>
          <volume>169</volume>
          <year>2002</year>
          <fpage>633</fpage>
          <lpage>637</lpage>
          <pub-id pub-id-type="pmid">12097362</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0760">
        <label>152</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shrikant</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Khoruts</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mescher</surname>
              <given-names>M.F.</given-names>
            </name>
          </person-group>
          <article-title>CTLA-4 blockade reverses CD8<sup>+</sup> T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism</article-title>
          <source>Immunity</source>
          <volume>11</volume>
          <year>1999</year>
          <fpage>483</fpage>
          <lpage>493</lpage>
          <pub-id pub-id-type="pmid">10549630</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0765">
        <label>153</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Latchman</surname>
              <given-names>Y.E.</given-names>
            </name>
            <name>
              <surname>Buhlmann</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Tomczak</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses</article-title>
          <source>Eur J Immunol</source>
          <volume>33</volume>
          <year>2003</year>
          <fpage>2706</fpage>
          <lpage>2716</lpage>
          <pub-id pub-id-type="pmid">14515254</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0770">
        <label>154</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keir</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Guleria</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Latchman</surname>
              <given-names>Y.E.</given-names>
            </name>
            <name>
              <surname>Qipo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Albacker</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Tissue expression of PD-L1 mediates peripheral T cell tolerance</article-title>
          <source>J Exp Med</source>
          <volume>203</volume>
          <year>2006</year>
          <fpage>883</fpage>
          <lpage>895</lpage>
          <pub-id pub-id-type="pmid">16606670</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0775">
        <label>155</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Butte</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Keir</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Phamduy</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</article-title>
          <source>Immunity</source>
          <volume>27</volume>
          <year>2007</year>
          <fpage>111</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="pmid">17629517</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0780">
        <label>156</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakae</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Suto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Iikura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kakurai</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sedgwick</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF</article-title>
          <source>J Immunol</source>
          <volume>176</volume>
          <year>2006</year>
          <fpage>2238</fpage>
          <lpage>2248</lpage>
          <pub-id pub-id-type="pmid">16455980</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0785">
        <label>157</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Lind</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Gondek</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Gleeson</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Pino-Lagos</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Mast cells are essential intermediaries in regulatory T-cell tolerance</article-title>
          <source>Nature</source>
          <volume>442</volume>
          <year>2006</year>
          <fpage>997</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="pmid">16921386</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0790">
        <label>158</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Francisco</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Salinas</surname>
              <given-names>V.H.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>K.E.</given-names>
            </name>
            <name>
              <surname>Vanguri</surname>
              <given-names>V.K.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Kuchroo</surname>
              <given-names>V.K.</given-names>
            </name>
          </person-group>
          <article-title>PD-L1 regulates the development, maintenance, and function of induced regulatory T cells</article-title>
          <source>J Exp Med</source>
          <volume>206</volume>
          <year>2009</year>
          <fpage>3015</fpage>
          <lpage>3029</lpage>
          <pub-id pub-id-type="pmid">20008522</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0795">
        <label>159</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Francisco</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Sage</surname>
              <given-names>P.T.</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>The PD-1 pathway in tolerance and autoimmunity</article-title>
          <source>Immunol Rev</source>
          <volume>236</volume>
          <year>2010</year>
          <fpage>219</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="pmid">20636820</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0800">
        <label>160</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Dorfman</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>F.R.</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>C.R.</given-names>
            </name>
          </person-group>
          <article-title>Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production</article-title>
          <source>J Immunol</source>
          <volume>170</volume>
          <year>2003</year>
          <fpage>1257</fpage>
          <lpage>1266</lpage>
          <pub-id pub-id-type="pmid">12538684</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0805">
        <label>161</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carter</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Fouser</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Jussif</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fitz</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>C.R.</given-names>
            </name>
          </person-group>
          <article-title>PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2</article-title>
          <source>Eur J Immunol</source>
          <volume>32</volume>
          <year>2002</year>
          <fpage>634</fpage>
          <lpage>643</lpage>
          <pub-id pub-id-type="pmid">11857337</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0810">
        <label>162</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishimura</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nose</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hiai</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Minato</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Honjo</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</article-title>
          <source>Immunity</source>
          <volume>11</volume>
          <year>1999</year>
          <fpage>141</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="pmid">10485649</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0815">
        <label>163</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishimura</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Nakatani</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Matsumori</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice</article-title>
          <source>Science (New York, NY)</source>
          <volume>291</volume>
          <year>2001</year>
          <fpage>319</fpage>
          <lpage>322</lpage>
        </element-citation>
      </ref>
      <ref id="bib0820">
        <label>164</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozkaynak</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Goodearl</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>O’Keefe</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Programmed death-1 targeting can promote allograft survival</article-title>
          <source>J Immunol</source>
          <volume>169</volume>
          <year>2002</year>
          <fpage>6546</fpage>
          <lpage>6553</lpage>
          <pub-id pub-id-type="pmid">12444166</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0825">
        <label>165</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Demirci</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Strom</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X.C.</given-names>
            </name>
          </person-group>
          <article-title>Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival</article-title>
          <source>Transplantation</source>
          <volume>76</volume>
          <year>2003</year>
          <fpage>994</fpage>
          <lpage>999</lpage>
          <pub-id pub-id-type="pmid">14508368</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0830">
        <label>166</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>del Rio</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Buhler</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rayat</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rodriguez-Barbosa</surname>
              <given-names>J.I.</given-names>
            </name>
          </person-group>
          <article-title>HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation</article-title>
          <source>J Leukoc Biol</source>
          <volume>87</volume>
          <year>2010</year>
          <fpage>223</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">20007250</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0835">
        <label>167</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sedy</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Gavrieli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Potter</surname>
              <given-names>K.G.</given-names>
            </name>
            <name>
              <surname>Hurchla</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Lindsley</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Hildner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator</article-title>
          <source>Nat Immunol</source>
          <volume>6</volume>
          <year>2005</year>
          <fpage>90</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">15568026</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0840">
        <label>168</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murphy</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Slow down and survive: enigmatic immunoregulation by BTLA and HVEM</article-title>
          <source>Annu Rev Immunol</source>
          <volume>28</volume>
          <year>2010</year>
          <fpage>389</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">20307212</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0845">
        <label>169</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watanabe</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gavrieli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sedy</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fallarino</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Loftin</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1</article-title>
          <source>Nat Immunol</source>
          <volume>4</volume>
          <year>2003</year>
          <fpage>670</fpage>
          <lpage>679</lpage>
          <pub-id pub-id-type="pmid">12796776</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0850">
        <label>170</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cai</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation</article-title>
          <source>Immunol Rev</source>
          <volume>229</volume>
          <year>2009</year>
          <fpage>244</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="pmid">19426226</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0855">
        <label>171</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cai</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Anumanthan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Greenfield</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator</article-title>
          <source>Nat Immunol</source>
          <volume>9</volume>
          <year>2008</year>
          <fpage>176</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">18193050</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0860">
        <label>172</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ye</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Busfield</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival</article-title>
          <source>J Exp Med</source>
          <volume>195</volume>
          <year>2002</year>
          <fpage>795</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="pmid">11901205</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0865">
        <label>173</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Truong</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Plester</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Kaye</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Merani</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival</article-title>
          <source>Transplantation</source>
          <volume>84</volume>
          <year>2007</year>
          <fpage>1368</fpage>
          <lpage>1372</lpage>
          <pub-id pub-id-type="pmid">18049125</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0870">
        <label>174</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Truong</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Plester</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Merani</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts</article-title>
          <source>Am J Transplant</source>
          <volume>7</volume>
          <year>2007</year>
          <fpage>2663</fpage>
          <lpage>2674</lpage>
          <pub-id pub-id-type="pmid">17983390</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0875">
        <label>175</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tao</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Honjo</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts</article-title>
          <source>J Immunol</source>
          <volume>175</volume>
          <year>2005</year>
          <fpage>5774</fpage>
          <lpage>5782</lpage>
          <pub-id pub-id-type="pmid">16237069</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0880">
        <label>176</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albring</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Sandau</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Rapaport</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Edelson</surname>
              <given-names>B.T.</given-names>
            </name>
            <name>
              <surname>Satpathy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mashayekhi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression</article-title>
          <source>J Exp Med</source>
          <volume>207</volume>
          <year>2010</year>
          <fpage>2551</fpage>
          <lpage>2559</lpage>
          <pub-id pub-id-type="pmid">21078889</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0885">
        <label>177</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khademi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Illes</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Gielen</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Marta</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Takazawa</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Baecher-Allan</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis</article-title>
          <source>J Immunol</source>
          <volume>172</volume>
          <year>2004</year>
          <fpage>7169</fpage>
          <lpage>7176</lpage>
          <pub-id pub-id-type="pmid">15153541</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0890">
        <label>178</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuchroo</surname>
              <given-names>V.K.</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>D.T.</given-names>
            </name>
            <name>
              <surname>DeKruyff</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>The TIM gene family: emerging roles in immunity and disease</article-title>
          <source>Nat Rev Immunol</source>
          <volume>3</volume>
          <year>2003</year>
          <fpage>454</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">12776205</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0895">
        <label>179</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez-Manzanet</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>DeKruyff</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kuchroo</surname>
              <given-names>V.K.</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>D.T.</given-names>
            </name>
          </person-group>
          <article-title>The costimulatory role of TIM molecules</article-title>
          <source>Immunol Rev</source>
          <volume>229</volume>
          <year>2009</year>
          <fpage>259</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="pmid">19426227</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0900">
        <label>180</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Umetsu</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>McIntire</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Downey</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sanjanwala</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Akbari</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>TIM-1 induces T cell activation and inhibits the development of peripheral tolerance</article-title>
          <source>Nat Immunol</source>
          <volume>6</volume>
          <year>2005</year>
          <fpage>447</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="pmid">15793575</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0905">
        <label>181</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakae</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Iikura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Suto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Akiba</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>D.T.</given-names>
            </name>
            <name>
              <surname>Dekruyff</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells</article-title>
          <source>Blood</source>
          <volume>110</volume>
          <year>2007</year>
          <fpage>2565</fpage>
          <lpage>2568</lpage>
          <pub-id pub-id-type="pmid">17620455</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0910">
        <label>182</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sizing</surname>
              <given-names>I.D.</given-names>
            </name>
            <name>
              <surname>Bailly</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>McCoon</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pablo</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses</article-title>
          <source>J Immunol</source>
          <volume>178</volume>
          <year>2007</year>
          <fpage>2249</fpage>
          <lpage>2261</lpage>
          <pub-id pub-id-type="pmid">17277130</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0915">
        <label>183</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feigelstock</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mattoo</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>G.G.</given-names>
            </name>
          </person-group>
          <article-title>The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor</article-title>
          <source>Journal of virology</source>
          <volume>72</volume>
          <year>1998</year>
          <fpage>6621</fpage>
          <lpage>6628</lpage>
          <pub-id pub-id-type="pmid">9658108</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0920">
        <label>184</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichimura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bonventre</surname>
              <given-names>J.V.</given-names>
            </name>
            <name>
              <surname>Bailly</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hession</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Cate</surname>
              <given-names>R.L.</given-names>
            </name>
          </person-group>
          <article-title>Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury</article-title>
          <source>The Journal of biological chemistry</source>
          <volume>273</volume>
          <year>1998</year>
          <fpage>4135</fpage>
          <lpage>4142</lpage>
          <pub-id pub-id-type="pmid">9461608</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0925">
        <label>185</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santiago</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ballesteros</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tami</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Martinez-Munoz</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>G.G.</given-names>
            </name>
            <name>
              <surname>Casasnovas</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family</article-title>
          <source>Immunity</source>
          <volume>26</volume>
          <year>2007</year>
          <fpage>299</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="pmid">17363299</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0930">
        <label>186</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyers</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Chakravarti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Schlesinger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Illes</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Waldner</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>TIM-4 is the ligand for TIM-1, and the TIM-1–TIM-4 interaction regulates T cell proliferation</article-title>
          <source>Nat Immunol</source>
          <volume>6</volume>
          <year>2005</year>
          <fpage>455</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="pmid">15793576</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0935">
        <label>187</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tami</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Silberstein</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Manangeeswaran</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>DeKruyff</surname>
              <given-names>R.H.</given-names>
            </name>
          </person-group>
          <article-title>Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus–receptor interactions</article-title>
          <source>J Virol</source>
          <volume>81</volume>
          <year>2007</year>
          <fpage>3437</fpage>
          <lpage>3446</lpage>
          <pub-id pub-id-type="pmid">17229699</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0940">
        <label>188</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kobayashi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Karisola</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pena-Cruz</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Dorfman</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Jinushi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells</article-title>
          <source>Immunity</source>
          <volume>27</volume>
          <year>2007</year>
          <fpage>927</fpage>
          <lpage>940</lpage>
          <pub-id pub-id-type="pmid">18082433</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0945">
        <label>189</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Degauque</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mariat</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kenny</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Vu</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice</article-title>
          <source>J Clin Invest</source>
          <volume>118</volume>
          <year>2008</year>
          <fpage>735</fpage>
          <lpage>741</lpage>
          <pub-id pub-id-type="pmid">18079964</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0950">
        <label>190</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueno</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Habicht</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Clarkson</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Albin</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Yamaura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Boenisch</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model</article-title>
          <source>J Clin Invest</source>
          <volume>118</volume>
          <year>2008</year>
          <fpage>742</fpage>
          <lpage>751</lpage>
          <pub-id pub-id-type="pmid">18172549</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0955">
        <label>191</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sabatos</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Chakravarti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cha</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Schubart</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sanchez-Fueyo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>X.X.</given-names>
            </name>
          </person-group>
          <article-title>Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance</article-title>
          <source>Nat Immunol</source>
          <volume>4</volume>
          <year>2003</year>
          <fpage>1102</fpage>
          <lpage>1110</lpage>
          <pub-id pub-id-type="pmid">14556006</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0960">
        <label>192</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez-Fueyo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Picarella</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Domenig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>X.X.</given-names>
            </name>
            <name>
              <surname>Sabatos</surname>
              <given-names>C.A.</given-names>
            </name>
          </person-group>
          <article-title>Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance</article-title>
          <source>Nat Immunol</source>
          <volume>4</volume>
          <year>2003</year>
          <fpage>1093</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="pmid">14556005</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0965">
        <label>193</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frisancho-Kiss</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nyland</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Gatewood</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Njoku</surname>
              <given-names>D.B.</given-names>
            </name>
          </person-group>
          <article-title>Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity</article-title>
          <source>J Immunol</source>
          <volume>176</volume>
          <year>2006</year>
          <fpage>6411</fpage>
          <lpage>6415</lpage>
          <pub-id pub-id-type="pmid">16709797</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0970">
        <label>194</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kamimura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Akiba</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yagita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Preferential involvement of Tim-3 in the regulation of hepatic CD8<sup>+</sup> T cells in murine acute graft-versus-host disease</article-title>
          <source>J Immunol</source>
          <volume>177</volume>
          <year>2006</year>
          <fpage>4281</fpage>
          <lpage>4287</lpage>
          <pub-id pub-id-type="pmid">16982862</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0975">
        <label>195</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Schubart</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Imitola</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Khoury</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity</article-title>
          <source>Nat Immunol</source>
          <volume>6</volume>
          <year>2005</year>
          <fpage>1245</fpage>
          <lpage>1252</lpage>
          <pub-id pub-id-type="pmid">16286920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0980">
        <label>196</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oomizu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sakata</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Sakata</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Arikawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis</article-title>
          <source>Clin Immunol (Orlando, FL)</source>
          <volume>127</volume>
          <year>2008</year>
          <fpage>78</fpage>
          <lpage>88</lpage>
        </element-citation>
      </ref>
      <ref id="bib0985">
        <label>197</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Mixed chimerism and transplantation tolerance</article-title>
          <source>Annu Rev Med</source>
          <volume>52</volume>
          <year>2001</year>
          <fpage>353</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">11160784</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0990">
        <label>198</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fudaba</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Spitzer</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Shaffer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Fehr</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Delmonico</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses</article-title>
          <source>Am J Transplant</source>
          <volume>6</volume>
          <year>2006</year>
          <fpage>2121</fpage>
          <lpage>2133</lpage>
          <pub-id pub-id-type="pmid">16796719</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0995">
        <label>199</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cosimi</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Spitzer</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Tolkoff-Rubin</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Suthanthiran</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Saidman</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>HLA-mismatched renal transplantation without maintenance immunosuppression</article-title>
          <source>N Engl J Med</source>
          <volume>358</volume>
          <year>2008</year>
          <fpage>353</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">18216355</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1000">
        <label>200</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ildstad</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Sachs</surname>
              <given-names>D.H.</given-names>
            </name>
          </person-group>
          <article-title>Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts</article-title>
          <source>Nature</source>
          <volume>307</volume>
          <year>1984</year>
          <fpage>168</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">6361574</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1005">
        <label>201</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Szot</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Swenson</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning</article-title>
          <source>Nat Med</source>
          <volume>3</volume>
          <year>1997</year>
          <fpage>783</fpage>
          <lpage>787</lpage>
          <pub-id pub-id-type="pmid">9212108</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1010">
        <label>202</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomita</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen</article-title>
          <source>J Immunol</source>
          <volume>153</volume>
          <year>1994</year>
          <fpage>1087</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="pmid">8027542</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1015">
        <label>203</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilat</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Transplantation tolerance through mixed chimerism</article-title>
          <source>Nat Rev</source>
          <volume>6</volume>
          <year>2010</year>
          <fpage>594</fpage>
          <lpage>605</lpage>
        </element-citation>
      </ref>
      <ref id="bib1020">
        <label>204</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharabi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sachs</surname>
              <given-names>D.H.</given-names>
            </name>
          </person-group>
          <article-title>Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen</article-title>
          <source>J Exp Med</source>
          <volume>169</volume>
          <year>1989</year>
          <fpage>493</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="pmid">2562984</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1025">
        <label>205</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sayegh</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Chandraker</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Swenson</surname>
              <given-names>K.G.</given-names>
            </name>
          </person-group>
          <article-title>Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance</article-title>
          <source>J Exp Med</source>
          <volume>187</volume>
          <year>1998</year>
          <fpage>2037</fpage>
          <lpage>2044</lpage>
          <pub-id pub-id-type="pmid">9625763</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1030">
        <label>206</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ronquillo</surname>
              <given-names>J.V.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment</article-title>
          <source>Nat Med</source>
          <volume>6</volume>
          <year>2000</year>
          <fpage>464</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="pmid">10742157</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1035">
        <label>207</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durham</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Bingaman</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Waitze</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.C.</given-names>
            </name>
          </person-group>
          <article-title>Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning</article-title>
          <source>J Immunol</source>
          <volume>165</volume>
          <year>2000</year>
          <fpage>1</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">10861026</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1040">
        <label>208</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilat</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Baranyi</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Klaus</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jaeckel</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mpofu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wrba</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning</article-title>
          <source>Am J Transplant</source>
          <volume>10</volume>
          <year>2010</year>
          <fpage>751</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="pmid">20148810</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1045">
        <label>209</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilat</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism</article-title>
          <source>Curr Opin Org Transplant</source>
          <volume>15</volume>
          <year>2010</year>
          <fpage>725</fpage>
          <lpage>730</lpage>
        </element-citation>
      </ref>
      <ref id="bib1050">
        <label>210</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Blaha</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Koporc</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bigenzahn</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pusch</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Muehlbacher</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral tolerance</article-title>
          <source>Transplantation</source>
          <volume>75</volume>
          <year>2003</year>
          <fpage>21S</fpage>
          <lpage>25S</lpage>
          <pub-id pub-id-type="pmid">12819486</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1055">
        <label>211</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Shaffer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lie</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Anosova</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Benichou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells</article-title>
          <source>Blood</source>
          <volume>103</volume>
          <year>2004</year>
          <fpage>4336</fpage>
          <lpage>4343</lpage>
          <pub-id pub-id-type="pmid">14962909</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1060">
        <label>212</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fehr</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Early regulation of CD8 T cell alloreactivity by CD4+CD25− T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8<sup>+</sup> T cells, precluding a role for sustained regulation</article-title>
          <source>Eur J Immunol</source>
          <volume>35</volume>
          <year>2005</year>
          <fpage>2679</fpage>
          <lpage>2690</lpage>
          <pub-id pub-id-type="pmid">16082727</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1065">
        <label>213</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sayegh</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bensinger</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death</article-title>
          <source>J Immunol</source>
          <volume>166</volume>
          <year>2001</year>
          <fpage>2311</fpage>
          <lpage>2316</lpage>
          <pub-id pub-id-type="pmid">11160287</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1070">
        <label>214</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haspot</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Fehr</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hogan</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Honjo</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway</article-title>
          <source>Blood</source>
          <volume>112</volume>
          <year>2008</year>
          <fpage>2149</fpage>
          <lpage>2155</lpage>
          <pub-id pub-id-type="pmid">18577709</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1075">
        <label>215</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lucas</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Workman</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Beyaz</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Locascio</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vignali</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>LAG-3, TGF-{beta}, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T cell tolerance induced by allogeneic BMT with anti-CD40L</article-title>
          <source>Blood</source>
          <year>2011</year>
        </element-citation>
      </ref>
      <ref id="bib1080">
        <label>216</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Raval</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Vallot</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Der</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance</article-title>
          <source>Blood</source>
          <volume>113</volume>
          <year>2009</year>
          <fpage>3475</fpage>
          <lpage>3484</lpage>
          <pub-id pub-id-type="pmid">19179471</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1085">
        <label>217</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bigenzahn</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Blaha</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Koporc</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Pree</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Selzer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Bergmeister</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade</article-title>
          <source>Am J Transplant</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>1237</fpage>
          <lpage>1247</lpage>
          <pub-id pub-id-type="pmid">15888027</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1090">
        <label>218</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Domenig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sanchez-Fueyo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Alexopoulos</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Mariat</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol</article-title>
          <source>J Immunol</source>
          <volume>175</volume>
          <year>2005</year>
          <fpage>51</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">15972631</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1095">
        <label>219</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurtz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wekerle</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Tolerance in mixed chimerism—a role for regulatory cells?</article-title>
          <source>Trends Immunol</source>
          <volume>25</volume>
          <year>2004</year>
          <fpage>518</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="pmid">15364053</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1100">
        <label>220</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Storb</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zaucha</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Deeg</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Georges</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kiem</surname>
              <given-names>H.P.</given-names>
            </name>
          </person-group>
          <article-title>Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant</article-title>
          <source>Blood</source>
          <volume>94</volume>
          <year>1999</year>
          <fpage>2523</fpage>
          <lpage>2529</lpage>
          <pub-id pub-id-type="pmid">10498626</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1105">
        <label>221</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jochum</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Beste</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zellmer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Graves</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Storb</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation</article-title>
          <source>Biol Blood Marrow Transplant</source>
          <volume>13</volume>
          <year>2007</year>
          <fpage>164</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="pmid">17241922</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1110">
        <label>222</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sogawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Boskovic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Abrahamian</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>R.N.</given-names>
            </name>
            <name>
              <surname>Wee</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates</article-title>
          <source>Am J Transplant</source>
          <volume>4</volume>
          <year>2004</year>
          <fpage>1391</fpage>
          <lpage>1398</lpage>
          <pub-id pub-id-type="pmid">15307826</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1115">
        <label>223</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cosimi</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Colvin</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Powelson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Eason</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kozlowski</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys</article-title>
          <source>Transplantation</source>
          <volume>59</volume>
          <year>1995</year>
          <fpage>256</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="pmid">7839449</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1120">
        <label>224</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoyama</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Millington</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Boskovic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wain</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of lung and kidney allografts in induction of tolerance by a mixed-chimerism approach in cynomolgus monkeys</article-title>
          <source>Transplant Proc</source>
          <volume>41</volume>
          <year>2009</year>
          <fpage>429</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="pmid">19249572</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1125">
        <label>225</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scandling</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Busque</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dejbakhsh-Jones</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Benike</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Millan</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Shizuru</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Tolerance and chimerism after renal and hematopoietic-cell transplantation</article-title>
          <source>N Engl J Med</source>
          <volume>358</volume>
          <year>2008</year>
          <fpage>362</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="pmid">18216356</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1130">
        <label>226</label>
        <mixed-citation publication-type="other">Andreola G, Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, et al. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant; in press.</mixed-citation>
      </ref>
      <ref id="bib1135">
        <label>227</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kean</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Strobert</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hendrix</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gangappa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T.R.</given-names>
            </name>
          </person-group>
          <article-title>Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression</article-title>
          <source>Am J Transplant</source>
          <volume>7</volume>
          <year>2007</year>
          <fpage>320</fpage>
          <lpage>335</lpage>
          <pub-id pub-id-type="pmid">17241112</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1140">
        <label>228</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Page</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Linzie</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Deane</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Stempora</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching</article-title>
          <source>Am J Transplant</source>
          <volume>10</volume>
          <year>2010</year>
          <fpage>2396</fpage>
          <lpage>2409</lpage>
          <pub-id pub-id-type="pmid">20849552</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1145">
        <label>229</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Blancho</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Durrbach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Friend</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Grinyo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Halloran</surname>
              <given-names>P.F.</given-names>
            </name>
          </person-group>
          <article-title>Five-year safety and efficacy of belatacept in renal transplantation</article-title>
          <source>J Am Soc Nephrol</source>
          <volume>21</volume>
          <year>2010</year>
          <fpage>1587</fpage>
          <lpage>1596</lpage>
          <pub-id pub-id-type="pmid">20634298</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1150">
        <label>230</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durrbach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pestana</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>V.D.</given-names>
            </name>
            <name>
              <surname>Campistol</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)</article-title>
          <source>Am J Transplant</source>
          <volume>10</volume>
          <year>2010</year>
          <fpage>547</fpage>
          <lpage>557</lpage>
          <pub-id pub-id-type="pmid">20415898</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1155">
        <label>231</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferguson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Grinyo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Vincenti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Woodle</surname>
              <given-names>E.S.</given-names>
            </name>
            <name>
              <surname>Marder</surname>
              <given-names>B.A.</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients</article-title>
          <source>Am J Transplant</source>
          <volume>11</volume>
          <year>2011</year>
          <fpage>66</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">21114656</pub-id>
        </element-citation>
      </ref>
      <ref id="bib1160">
        <label>232</label>
        <mixed-citation publication-type="other">Riella LV, Sayegh MH. T cell costimulatory blockade in kidney transplantation: back to the bench. Kidney Int; in press.</mixed-citation>
      </ref>
      <ref id="bib1165">
        <label>233</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouguermouh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fortin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Baba</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Rubio</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sarfati</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>CD28 co-stimulation down regulates Th17 development</article-title>
          <source>PLoS One</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>e5087</fpage>
          <pub-id pub-id-type="pmid">19333372</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgements</title>
      <p>Some of the work described in this review was supported by a research grant from the Austrian Science Fund (FWF, TRP151-B19 to T.W.) and by NIAID RO1 AI 51559 and R01 AI 070820-01A1 for MHS.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig0005">
      <label>Fig. 1</label>
      <caption>
        <p>Costimulatory pathways relevant in transplantation. (a) Expression patterns of costimulatory molecules on T cells and APC are depicted. Categorization according to structure and function as positive or negative signalling pathway are indicated. (b) Costimulation blockers in (pre)clinical development and their ligands are depicted. Signals inhibited by these compounds are shown in grey.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
  </floats-group>
</article>